Novel benzothiophene derivative inhibiting bet protein and composition for treatment of cancer, using same

A novel benzothiophene derivative targeting BRD2 protein effectively addresses the limitations of current bromodomain inhibitors by inhibiting BET proteins in cancer treatment, offering a potential solution for recurrence and side effects through redox state-aware mechanisms.

WO2024232599A1PCT designated stage expired Publication Date: 2024-11-14BENOBIO CO LTD
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2024/005962
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-09
Filing Date
2024-05-02
Publication Date
2024-11-14

AI Technical Summary

Technical Problem

Current bromodomain inhibitors face challenges with disease recurrence and resistance to therapeutic agents, as well as side effects, and there is a need for new inhibitors that consider redox state mechanisms in cancer treatment.

Method used

A novel benzothiophene derivative with excellent binding ability to BRD2 protein, inhibiting BET proteins, is developed, which forms the basis of a pharmaceutical composition for preventing or treating cancer, taking into account redox chemistry and the varying binding states of signaling substances.

Benefits of technology

The novel benzothiophene derivative effectively inhibits BET proteins, providing a promising approach for cancer treatment by targeting BRD2, potentially overcoming recurrence and resistance issues while minimizing side effects through redox state consideration.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PCTKR2024005962-APPB-IMG-000001
    Figure PCTKR2024005962-APPB-IMG-000001
  • Figure PCTKR2024005962-APPB-IMG-000002
    Figure PCTKR2024005962-APPB-IMG-000002
  • Figure PCTKR2024005962-APPB-IMG-000003
    Figure PCTKR2024005962-APPB-IMG-000003
Patent Text Reader

Abstract

The present invention relates to a novel benzothiophene derivative exhibiting inhibitory activity against a bromodomain and extra-terminal (BET) protein, and a composition for prevention or treatment of cancer, comprising same as an active ingredient.
Need to check novelty before this filing date? Find Prior Art

Description

A novel benzothiophene derivative that inhibits BET protein and a composition for treating cancer using the same

[0001] The present invention relates to a novel benzothiophene derivative exhibiting BET (Bromodomain Extra-Terminal) protein inhibitory activity and a composition for preventing or treating cancer comprising the same as an active ingredient. Specifically, the novel benzothiophene derivative of the present invention has excellent binding affinity to BRD2 protein among BET proteins, thereby exhibiting an inhibitory activity against BRD2 protein, and can provide a pharmaceutical composition for preventing or treating cancer using the same.

[0002] DNA is packaged into chromatin by wrapping around a core of histone proteins, forming nucleosomes. These nucleosomes, in turn, form a compact chromatin structure through aggregation and folding. Chromatin structure plays a crucial role in regulating gene transcription by controlling protein access to DNA and is controlled primarily by a series of posttranslational modifications to histone proteins, primarily within the histone H3 and H4 tails that extend behind the core nucleosome structure. These modifications include acetylation, methylation, phosphorylation, ubiquitination, and SUMOlylation.

[0003] Post-translational modifications (PTMs) of histones are involved in the regulation of gene expression and chromatin organization in eukaryotic cells. Histone acetylation at specific lysine residues is a PTM regulated by histone acetylases and histone deacetylases. Histone acetylation regulates gene expression by recruiting a protein complex, called a bromodomain, which directly binds to acetylated lysines on histones and other proteins. More than 60 bromodomain-containing proteins exist in the human genome.

[0004] The BET (Bromodomain and Extra-Terminal) family of bromodomain-containing proteins includes four proteins (BRD2, BRD3, BRD4, and BRD-t) that share a conserved structural organization containing tandem N-terminal bromodomains that can bind to acetylated lysine residues in histones and other proteins. BRD2, BRD3, and BRD4 are widely expressed in various tissues, whereas BRD-t is restricted to germ cells. BRD proteins play essential but non-overlapping roles in regulating gene transcription and controlling cell growth. BET proteins associate with large protein complexes containing the Mediator, PAFc, and the super-elongated complex, which regulates many aspects of gene transcription. BRD2 and BRD4 proteins have been shown to complex with chromosomes during mitosis and to be required for promoting transcription of key genes, including cyclin D and c-Myc, which initiate the cell cycle (Mochizuki J Biol. Chem. 2008 283:9040-9048). BRD2 and BRD3 have been reported to associate with histones along actively transcribed genes and may be involved in promoting transcription elongation (Leroy et al, Mol. Cell. 2008 30:51-60). BRD4 is essential for recruiting the protein translation elongation factor B complex to the promoters of inducible genes, which leads to phosphorylation of RNA polymerase II and stimulates productive gene transcription and elongation (Jang et al. Mol. Cell 2005 19:523-534). In some cases, the kinase activity of BRD4 can directly phosphorylate and activate RNA polymerase II (Devaiah et al. PNAS 2012 109:6927–6932). Cells lacking BRD4 exhibit impaired progression through the cell cycle.

[0005] Recurrent translocations involving NUT (nuclear protein in testis) with BRD3 or BRD4 to form a novel fusion oncogene, BRD-NUT, are found in highly malignant forms of epithelial neoplasia (French et al, Cancer Research 2003 63:304-307; French et al, Journal of Clinical Oncology 2004 22:4135-4139). Selective ablation of this oncogene restores normal cell differentiation and reverses the tumorigenic phenotype (Filippakopoulos et al, Nature 2010 468:1068-1073). Genetic knockout of BRD2, BRD3, and BRD4 has been shown to impair the growth and viability of a wide range of hematological and solid tumor cells (Zuber et al, Nature 2011 478:524-528; Delmore et al, Cell 2011 146:904-917).

[0006] For example, oncogenic fusions of the BRD4 or BRD3 and NUT genes, caused by chromosomal translocations, result in an aggressive cancer called NUT midline carcinoma (French et al., J Clin Oncol, 22 (2004), 4135-9; French et al., J Clin Pathol, 63 (2008), 492-6). The BRD3 / 4 bromodomain is conserved in these fusion proteins, and knockdown or the selective BET bromodomain inhibitor JQ1 causes cell death of these cancer cells both in vitro and in animal tumor models (Filippakopoulos et al., Nature, 468 (2010), 1067-73). JQ1 and other selective BET inhibitors are known to bind to the BET bromodomain and prevent acetyl-lysine linkage, which prevents BET proteins from interacting with chromatin and thereby regulating transcription.

[0007] BRD4 was identified as a target in acute myeloid leukemia (AML) using an RNAi screen (Zuber et al., Nature, 478 (2011), 524-8). This finding was validated in vitro and in vivo using the BET inhibitors JQ1 and I-BET151 (Dawson et al., Nature, 478 (2011), 529-33). Furthermore, BET inhibitors are known to have broad anticancer activity in acute leukemia, multiple myeloma, and other hematological malignancies. Acute downregulation of the oncogenic transcription factor Myc has been observed upon BET inhibition in several cancer models (Delmore et al., Cell, 146 (2011), 904-17; Mertz et al., Proc Natl Acad Sci US A, 108 (2011), 16669-74). Recent studies suggest that BET inhibitors may have broader application in other cancers, such as lung and brain cancer.

[0008] I-BET762, another BET inhibitor closely related to JQ1 in chemical structure and BET binding mode, has been reported to modulate the expression of key inflammatory genes in mouse models and protect against endotoxin shock and bacteria-induced sepsis (Nicodeme et al., Nature, 468 (2010), 1119-23). ​​Furthermore, these results have been used to support the clinical evaluation of the BET inhibitor RVX-208 in clinical trials in patients with atherosclerosis, coronary artery disease, dyslipidemia, diabetes, and other cardiovascular diseases (McNeill, Curr Opin Investig Drugs, 3 (2010), 357-64, and www.clinicaltrials.gov).

[0009] Both RVX-208 and I-BET762 have been shown to upregulate apolipoprotein AI, which is important in reducing tissue cholesterol levels. Furthermore, BET proteins have been implicated in the regulation of replication and transcription of several viruses, suggesting that BET inhibitors may have antiviral activity (Weidner-Glunde, Frontiers in Bioscience 15 (2010), 537-549).

[0010] Against this backdrop, the inventors of the present invention have completed the present invention by confirming that a novel BET inhibitory small molecule synthetic substance exhibiting excellent inhibitory ability against the BET protein, an epigenetic recognition agent, has excellent anticancer effects.

[0011] Although several bromodomain inhibitors are known in clinical and preclinical studies, there is an urgent need to develop new bromodomain inhibitors that can address the problems of disease recurrence and drug resistance and have reduced side effects.

[0012] Meanwhile, redox reactions are present in many physiological processes, and while molecular oxygen is essential for life, it can generate reactive molecules that lead to disease. Other reactive chemical species, including free radicals, also contribute to pathological conditions. It has long been known that aerobic metabolism, associated with tissue damage, is driven by reactive oxygen species (ROS). Like hormones, ROS and more recently, reactive nitrogen species (RNS), act as messengers of cell signaling, inducing chemical modifications of enzymes and altering oxidant levels.

[0013] Furthermore, among the 20 essential amino acids, cysteine, methionine, tyrosine, and tryptophan are particularly susceptible to oxidation. Consequently, these protein substances metabolized within the human body undergo various modifications, including metal binding, disulfide bond formation, methylation, and acetylation.

[0014] Although research on the signal regulation mechanism of cells has focused on phosphorylation to date, the present invention was completed by applying redox chemistry technology that considers redox regulation mechanisms such as oxidation and nitrosylation (S-nitrosylation) according to the "redox state" for diseases caused by oxidative and nitrosative stress. That is, the present inventors studied and developed a new bromodomain inhibitor considering the redox state, based on the fact that the degree of binding between signal transmission substances varies depending on the redox state when a BET inhibitor recognizes a lysine residue of a histone protein.

[0015] [Prior Art Literature]

[0016] [Patent Document 1]

[0017] Domestic Patent No. 10-2399206

[0018] [Non-patent document 1]

[0019] French et al., J Clin Oncol, 22 (2004), 4135-9; French et al., J Clin Pathol, 63 (2008), 492-6

[0020] The present invention provides a novel benzothiophene derivative exhibiting BET (Bromodomain Extra-Terminal) protein inhibitory activity, and relates to a composition for preventing or treating cancer comprising the same as an active ingredient. Specifically, the novel benzothiophene derivative of the present invention has excellent binding affinity to BRD2 protein among BET proteins, thereby exhibiting an inhibitory activity against BRD2 protein, and can provide a pharmaceutical composition for preventing or treating cancer using the same.

[0021] To solve the above problem, the present invention provides a compound, solvate, stereoisomer or pharmaceutically acceptable salt thereof of the following chemical formula I:

[0022] [Chemical Formula I]

[0023]

[0024] In the above formula,

[0025] X is hydrogen, C 1-6 Alkyl, C 1-6 alkylC(=O)N(Ra)(Rb), cycloalkyl, heterocycloalkyl, aryl or heteroaryl,

[0026] Y is hydrogen, C 1-6 alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl,

[0027] Z is -OH, -OC 1-6 Alkyl, hydrogen, C 1-6 Containing at least one selected from the group consisting of alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl,

[0028] C of the above X 1-6 Alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is C 1-6 At least one of the hydrogens of alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is -OH, heterocycloalkyl, C 3-6It may be substituted with one or more selected from the group consisting of cycloalkyl and heteroaryl,

[0029] C of the above Y 1-6 Alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is C 1-6 At least one of the hydrogens of alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is -OH, heterocycloalkyl, C 3-6 It may be substituted with one or more selected from the group consisting of cycloalkyl and heteroaryl.

[0030] In addition, the present invention provides a pharmaceutical composition for preventing or treating cancer, comprising the compound, solvate, stereoisomer or pharmaceutically acceptable salt thereof as an active ingredient.

[0031] The compound of formula I, a solvate, a stereoisomer, or a pharmaceutically acceptable salt thereof according to the present invention exhibits excellent BET protein inhibition effects and effectively inhibits the BRD2 protein among BET proteins. This BET protein inhibition effect can be utilized in the prevention and treatment of various cancers, including ovarian cancer. Therefore, the compound of formula I, a solvate, a stereoisomer, or a pharmaceutically acceptable salt thereof can be usefully used in the prevention and treatment of cancer.

[0032] Hereinafter, various embodiments of the present invention will be described with reference to the accompanying drawings. It should be understood that the present invention is not limited to specific embodiments, but rather encompasses various modifications, equivalents, and / or alternatives of the embodiments of the present invention. In the description of the drawings, similar reference numerals may be used for similar components.

[0033] In this document, the expressions “has”, “may have”, “includes”, or “may include” indicate the presence of a feature (e.g., a number, function, operation, or component such as a part), but do not exclude the presence of additional features.

[0034] In this document, the expressions "A or B," "at least one of A and / or B," or "one or more of A and / or B" can include all possible combinations of the listed items. For example, "A or B," "at least one of A and B," or "at least one of A or B" can all refer to cases where (1) at least one A is included, (2) at least one B is included, or (3) at least one A and at least one B are included.

[0035] The expression "configured to" as used herein can be used interchangeably with, for example, "suitable for", "having the capacity to", "designed to", "adapted to", "made to", or "capable of". The term "configured to" does not necessarily mean "specifically designed to".

[0036] The terms used in this document are used only to describe specific embodiments and may not be intended to limit the scope of other embodiments. The singular expression may include the plural expression unless the context clearly indicates otherwise. Terms used herein, including technical or scientific terms, may have the same meaning as commonly understood by those of ordinary skill in the art described in this document. Terms defined in general dictionaries among the terms used in this document may be interpreted as having the same or similar meaning in the context of the relevant technology, and shall not be interpreted in an idealized or overly formal sense unless explicitly defined in this document. In some cases, even if a term is defined in this document, it cannot be interpreted to exclude the embodiments of this document.

[0037] The embodiments disclosed in this document are presented for the purpose of explaining and understanding the disclosed technical content and are not intended to limit the scope of the present invention. Therefore, the scope of this document should be interpreted to include all modifications or various other embodiments based on the technical concept of the present invention.

[0038] Hereinafter, preferred embodiments of the present invention will be described in detail. Prior to this, it should be noted that the terms and words used in this specification and claims should not be construed as limited to their conventional or dictionary meanings. Based on the principle that the inventor can appropriately define the concepts of terms to best explain his or her invention, they should be interpreted in a way that aligns with the technical spirit of the present invention.

[0039] Accordingly, the configurations of the embodiments described in this specification are only some of the most preferred embodiments of the present invention and do not represent all of the technical ideas of the present invention, so it should be understood that there may be various equivalents and modified examples that can replace them at the time of filing this application.

[0040] Throughout the specification, whenever a part is said to "include" a component, this does not mean that it excludes other components, but rather that it may include other components, unless otherwise stated.

[0041] Hereinafter, the present invention will be described in detail.

[0042]

[0043] The present invention relates to a compound represented by Chemical Formula 1, and more specifically, to a novel benzothiophene derivative compound having inhibitory activity against BET protein and a pharmaceutical composition for preventing or treating cancer comprising the same.

[0044] [Chemical Formula I]

[0045] .

[0046] Unless otherwise stated, terms used in the description and claims of the present invention have the meanings set forth below.

[0047] According to the custom used in the art, in the chemical formula of this application " " is used to indicate that a residue or substituent "R" is attached to the skeletal structure.

[0048] "Alkyl" is a hydrocarbon group having primary, secondary, tertiary and / or quaternary carbon atoms, and includes saturated aliphatic groups which may be straight-chain, branched or cyclic, or a combination thereof. For example, an alkyl group may have from 1 to 20 carbon atoms (i.e., C1-C 20 alkyl), 1 to 10 carbon atoms (i.e., C1-C 10alkyl), or may have 1 to 6 carbon atoms (i.e., C1-C6 alkyl). Unless otherwise defined, in a preferred embodiment, alkyl refers to C1-C6 alkyl. Examples of suitable alkyl groups include methyl (Me, -CH3), ethyl (Et, -CH2CH3), 1-propyl (n-Pr, n-propyl, -CH2CH2CH3), 2-propyl (i-Pr, i-propyl, -CH(CH3)2), 1-butyl (n-Bu, n-butyl, -CH2CH2CH2CH3), 2-methyl-1-propyl (i-Bu, i-butyl, -CH2CH(CH3)2), 2-butyl (s-Bu, s-butyl, -CH(CH3)CH2CH3), 2-methyl-2-propyl (t-Bu, t-butyl, -C(CH3)3), 1-pentyl (n-pentyl, -CH2CH2CH2CH2CH3), 2-pentyl (-CH(CH3)CH2CH2CH3), 3-pentyl (-CH(CH2CH3)2), 2-Methyl-2-butyl (-C(CH3)2CH2CH3), 3-methyl-2-butyl (-CH(CH3)CH(CH3)2), 3-methyl-1-butyl (-CH2CH2CH(CH3)2), 2-methyl-1-butyl (-CH2CH(CH3)CH2CH3), 1-hexyl (-CH2CH2CH2CH2CH2CH3), 2-hexyl (-CH(CH3)CH2CH2CH2CH3), 3-hexyl (-CH(CH2CH3)(CH2CH2CH3)), 2-methyl-2-pentyl (-C(CH3)2CH2CH2CH3), 3-methyl-2-pentyl (-CH(CH3)CH(CH3)CH2CH3), 4-methyl-2-pentyl (-CH(CH3)CH2CH(CH3)2), 3-methyl-3-pentyl (-C(CH3)(CH2CH3)2), 2-methyl-3-pentyl (-CH(CH2CH3)CH(CH3)2), 2,3-dimethyl-2-butyl (-C(CH3)2CH(CH3)2), 3,3-dimethyl-2-butyl (-CH(CH3)C(CH3)3), and octyl (-(CH2)7CH3).

[0049] Moreover, the term "alkyl" as used throughout the specification, examples and claims is intended to encompass both unsubstituted and substituted alkyl groups, the latter of which refers to alkyl moieties having substituents replacing hydrogens on one or more carbons of the hydrocarbon backbone, including haloalkyl groups such as trifluoromethyl and 2,2,2-trifluoroethyl.

[0050] The term "C x-y " or "C x -C y "When used with chemical moieties such as acyl, acyloxy, alkyl, alkenyl, alkynyl or alkoxy, it is considered to include groups containing x to y carbons in the chain. C0 alkyl represents hydrogen when the group is at a terminal position and a bond when it is internal. For example, a (C1-C6) alkyl group contains 1 to 6 carbon atoms in the chain.

[0051] "Alkoxy" refers to a group having the formula -O-alkyl, wherein the alkyl group as defined above is attached to the parent compound through an oxygen atom. The alkyl moiety of an alkoxy group may, for example, be a group having from 1 to 20 carbon atoms (i.e., C1-C 20 alkoxy), 1 to 12 carbon atoms (i.e., C1-C 12 alkoxy), 1 to 10 carbon atoms (i.e. C1-C 10 alkoxy), or may have 1 to 6 carbon atoms (i.e., C1-C6alkoxy). Examples of suitable alkoxy groups include, but are not limited to, methoxy (-O-CH3 or -OMe), ethoxy (-OCH2CH3 or -OEt), and t-butoxy (-OC(CH3)3 or -O-tBu).

[0052] "Alkenyl" means a group having primary, secondary, tertiary and / or quaternary carbon atoms, including straight-chain, branched and cyclic groups, or combinations thereof, and having one or more regions of unsaturation, i.e., carbon-carbon sp 2A hydrocarbon with a double bond. For example, an alkenyl group has 2 to 20 carbon atoms (i.e., C2-C 20 alkenyl), 2 to 12 carbon atoms (i.e., C2-C 12 alkenyl), 2 to 10 carbon atoms (i.e., C2-C 10 alkenyl), or may have 2 to 6 carbon atoms (i.e., C2-C6 alkenyl). Examples of suitable alkenyl groups include, but are not limited to, vinyl (-CH=CH2), allyl (-CH2CH=CH2), cyclopentenyl (-C5H7), and 5-hexenyl (-CH2CH2CH2CH2CH=CH2).

[0053] "Alkynyl" is a hydrocarbon having primary, secondary, tertiary and / or quaternary carbon atoms, including straight-chain, branched and cyclic groups, or combinations thereof, and having at least one carbon-carbon sp triple bond. For example, an alkynyl group has from 2 to 20 carbon atoms (i.e., C2-C 20 alkynyl), 2 to 12 carbon atoms (i.e., C2-C 12 alkynyl), 2 to 10 carbon atoms (i.e., C2-C 10 alkynyl), or may have 2 to 6 carbon atoms (i.e., C2-C6alkynyl). Examples of suitable alkynyl groups include, but are not limited to, acetylenyl (-C≡CH) and propynyl (-CH2C≡CH).

[0054] As used herein, the term "aryl" includes substituted or unsubstituted monovalent or divalent aromatic hydrocarbon groups, which are monocyclic, bicyclic, or polycyclic, each ring atom being carbon. Preferably, the aryl ring is a 6- to 20-membered ring, a 6- to 14-membered ring, a 6- to 10-membered ring, or more preferably a 6-membered ring. An aryl group may be a polycyclic ring system having two or more cyclic rings in which two or more carbons are common to two adjacent rings, wherein at least one of the rings is aromatic, for example, the other cyclic ring may be a cycloalkyl, a cycloalkenyl, a cycloalkynyl, an aryl, a heteroaryl, and / or a heterocycloalkyl. Aryl groups include benzene, naphthalene, phenanthrene, anthracene, indene, indane, phenol, aniline, and the like.

[0055] The term "carbocyclylalkyl", or "cycloalkylalkyl", or "(cycloalkyl)alkyl" as used herein refers to an alkyl group substituted with a carbocycle group or a cycloalkyl group.

[0056] The terms "carbocycle," "carbocyclyl," "carbocyclic," or "cycloalkyl," as used herein, refer to a non-aromatic, saturated or unsaturated, monovalent or divalent ring, which may be monocyclic, bicyclic, or polycyclic, and wherein each ring atom is carbon. A cycloalkyl group may have 3 to 7 carbon atoms as a monocycle, 7 to 12 carbon atoms as a bicycle, and up to about 20 carbon atoms as a polycycle. A monocyclic cycloalkyl has 3 to 7 ring atoms, more typically 5 or 6 ring atoms. A bicyclic cycloalkyl may have 7 to 12 ring atoms, and may be a fused ring system, a spirocyclic ring system, or a bridged ring system. In exemplary cycloalkyl groups, the atoms may be arranged in a bicyclo[4,5], [5,5], [5,6], or [6,6] system. In certain embodiments, the cycloalkyl contains 3 to 20 atoms, or 3 to 10 atoms, or more preferably 3 to 7 atoms. Examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and the like. Unless otherwise specified, the cycloalkyl may be substituted with one or more substituents described herein.

[0057] The terms “heterocyclylalkyl” and “heterocycloalkyl” as used herein refer to an alkyl group substituted with a heterocycloalkyl group.

[0058] The terms "heterocyclyl", "heterocycle", "heterocyclic", and "heterocycloalkyl" refer to a substituted or unsubstituted, monovalent or divalent, saturated or partially saturated non-aromatic ring structure, preferably a 3- to 10-membered ring, more preferably a 3- to 7-membered ring, wherein the ring structure comprises one or more heteroatoms, preferably 1 to 4 heteroatoms, more preferably 1 to 2 heteroatoms. The terms "heterocyclyl," "heterocycle," "heterocyclic," and "heterocycloalkyl" also include polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjacent rings, wherein at least one of the rings is heterocyclic, for example, the other cyclic ring can be a cycloalkyl, a cycloalkenyl, a cycloalkynyl, an aryl, a heteroaryl, and / or a heterocyclyl. Bicyclic and polycyclic heterocyclic ring systems can be fused, bridged, or spiro ring systems. Substituted heterocycles include, for example, heterocyclic rings substituted with any of the substituents disclosed herein, including a carbonyl group. Heterocyclic groups include, for example, piperidine, piperazine, pyrrolidine, morpholine, lactones, lactams, and the like.Additionally, exemplary heterocycles include dihydropyridyl, dihydroindolyl, tetrahydropyridyl (piperidyl), tetrahydrothiophenyl, sulfur-oxidized tetrahydrothiophenyl, indolenyl, piperidinyl, 4-piperidinyl, pyrrolidinyl, 2-pyrrolidonyl, pyrrolinyl, tetrahydrofuranyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, octahydroisoquinolinyl, 6H-1,2,5-thiadiazinyl, 2H,6H-1,5,2-dithiazinyl, pyranyl, chromenyl, xanthenyl, phenoxathinyl, 2H-pyrrolyl, 3H-indolyl, 4H-quinolizinyl, phthalazinyl, naphthyridinyl, quinoxalinyl, Examples include, but are not limited to, quinazolinyl, cinnolinyl, pteridinyl, 4aH-carbazolyl, carbazolyl, B-carbolinyl, phenanthridinyl, acridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, furazanyl, phenoxazinyl, isochromanyl, chromanyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperazinyl, methyl piperazinyl, quinuclidinyl, morpholinyl, azabicyclo(2.1.1)hexanyl, azacycloheptanyl, 1-oxa-3-aza-cycloheptanyl, azetidinyl, aziridinyl, and oxazolidinyl (each of which may be substituted or unsubstituted).

[0059] "Heteroaryl" refers to a substituted or unsubstituted monovalent or divalent aromatic group, which is monocyclic, bicyclic or polycyclic, containing one or more heteroatoms in the ring. Non-limiting examples of suitable heteroatoms that can be contained in the aromatic ring include oxygen, sulfur and nitrogen. In a polycyclic heteroaryl ring system, the ring system has two or more cyclic rings in which two or more carbons are common to two adjacent rings, wherein at least one of the rings is heteroaromatic, for example, the other cyclic ring can be a cycloalkyl, a cycloalkenyl, a cycloalkynyl, an aryl, a heteroaryl, and / or a heterocyclyl. Heterocyclic groups include, for example, benzofuran, benzothiophene, pyrrole, furan, thiophene, imidazole, indole, isoindole, isoxazole, isothiazole, oxazole, thiazole, quinoline, isoquinoline, pyrazole, pyridine, pyrazine, pyridazine, and pyrimidine, each of which may be substituted or unsubstituted.

[0060] As used herein, the terms “halo” and “halogen” mean halogen, including chloro, fluoro, bromo, and iodine.

[0061] "Amino" represents the -NH2 group.

[0062] "Carboxy" refers to the -C(O)OH group.

[0063] "Aldehyde" represents the -CHO group.

[0064] The present invention relates to a compound of the following formula I, a solvate, a stereoisomer or a pharmaceutically acceptable salt thereof.

[0065] [Chemical Formula I]

[0066]

[0067] In the above formula,

[0068] X is hydrogen, C 1-6 Alkyl, C 1-6alkylC(=O)N(Ra)(Rb), cycloalkyl, heterocycloalkyl, aryl or heteroaryl,

[0069] Y is hydrogen, C 1-6 alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl,

[0070] Z is -OH, -OC 1-6 Alkyl, hydrogen, C 1-6 Containing at least one selected from the group consisting of alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl,

[0071] C of the above X 1-6 Alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is C 1-6 At least one of the hydrogens of alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is -OH, heterocycloalkyl, C 3-6 It may be substituted with one or more selected from the group consisting of cycloalkyl and heteroaryl,

[0072] C of the above Y 1-6 Alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is C 1-6 At least one of the hydrogens of alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is -OH, heterocycloalkyl, C 3-6 It may be substituted with one or more selected from the group consisting of cycloalkyl and heteroaryl.

[0073] In one embodiment, Ra and Rb are each independently H, C 1-6 It may include at least one selected from the group consisting of alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl,

[0074] R can be H.

[0075] In one embodiment, X is C 1-6 Alkyl or C 1-6 AlkylC(=O)N(Ra)(Rb),

[0076] C above 1-6 Alkyl is C 1-6 At least one of the hydrogens of the alkyl may be substituted with one or more of -OH or heterocycloalkyl,

[0077] The above Ra and Rb are each independently H or C 1-6 may contain one or more of alkyl,

[0078] The above heterocycloalkyl may be aziridinyl.

[0079] In one embodiment, Y is aryl or -C 1-6 It is alkyl,

[0080] C above 1-6 Alkyl is C 1-6 At least one of the hydrogens of alkyl is heterocycloalkyl, C 3-6 It may be substituted with one or more selected from the group consisting of cycloalkyl and heteroaryl,

[0081] The above aryl may include at least one benzyl or benzyl in which at least one of hydrogen is substituted with CN,

[0082] C above 3-6 Cycloalkyl is cyclohexyl,

[0083] The above heterocycloalkyl comprises at least one selected from the group consisting of morpholinyl, piperidinyl and piperazinyl,

[0084] The above heteroaryl is at least one of hydrogen or carbon, oxygen, carbon, nitrogen, fluorine and C 1-6 It may be a heteroaryl substituted with one or more substituents selected from the group consisting of alkyl.

[0085] In another embodiment, Z is hydrogen, C 1-6 Alkyl, C3 -6 Containing at least one selected from the group consisting of cycloalkyl, heterocycloalkyl, aryl and heteroaryl,

[0086] The above heteroaryl is at least one of hydrogen or carbon, oxygen, carbon, nitrogen, C 1-6 Alkyl, OC 1-6 It may be benzyl substituted with one or more substituents selected from the group consisting of alkyl and =O.

[0087] In addition, the present invention is not limited to a compound of formula I, a solvate, a stereoisomer or a pharmaceutically acceptable salt thereof selected from the group consisting of compounds represented by the chemical formulas of [Table 1] below.

[0088] [Table 1]

[0089]

[0090]

[0091]

[0092]

[0093]

[0094]

[0095]

[0096]

[0097]

[0098]

[0099]

[0100]

[0101]

[0102]

[0103]

[0104]

[0105]

[0106]

[0107]

[0108]

[0109] In addition, the present invention relates to a pharmaceutical composition for preventing or treating cancer, comprising a compound of the above chemical formula I, a solvate, a stereoisomer or a pharmaceutically acceptable salt thereof as an active ingredient.

[0110] The above cancers are adrenal cancer, acinar cell carcinoma, acoustic neuroma, acral lentigo melanoma, acral hidradenoma, acute eosinophilic leukemia, acute erythroleukemia, acute lymphoblastic leukemia, acute megakaryoblastic leukemia, acute monocytic leukemia, acute promyelocytic leukemia, adenocarcinoma, adenoma, adenomatoid odontogenic tumor, adenosquamous cell carcinoma, adipose tissue neoplasm, adrenocortical carcinoma, adult T-cell leukemia / lymphoma, aggressive NK-cell leukemia, AIDS-related lymphoma, alveolar rhabdomyomas, alveolar soft part sarcoma, ameloblastic fibrodentoma, anaplastic large cell lymphoma, anaplastic thyroid cancer, angioimmunoblastic T-cell lymphoma, angiomyolipoma, angiosarcoma, astrocytoma, atypical organotypic rod-shaped tumor, B-cell chronic lymphocytic leukemia, B-cell prolymphocytic Leukemia, B-cell lymphoma, basal cell carcinoma, cholangiocarcinoma, bladder cancer, blastoma, bone cancer, Brenner tumor, Brown tumor, Burkitt lymphoma, breast cancer, brain cancer, carcinoma, carcinoma in situ, carcinosarcoma, cartilaginous tumor, cementoma, myeloid sarcoma, chondroma, chordoma, choroidal carcinoma, choroid plexus papilloma, clear-cell sarcoma of the kidney, craniopharyngioma, cutaneous T-cell lymphoma, cervical cancer, colorectal cancer, Digos disease, desmoplastic small cell tumor, diffuse large B-cell lymphoma, dysembryonic neuroepithelial tumor, anaplastic stromal tumor, embryonal carcinoma, endocrine neoplasm, endodermal sinus tumor, combined T-cell lymphoma, esophageal cancer, fetus within the fetus, fibroma, fibrosarcoma, follicular lymphoma, follicular thyroid cancer, gangliocytoma, gastrointestinal cancer, germ cell tumor, gestational trophoblastic carcinoma, giant cell fibroblastoma, Giant cell tumor of bone, glial cell tumor, glioblastoma multiforme, glioma, cerebral gliomatosis, glucagonoma, gonadoblastoma, granulosa cell tumor, gonadoblastoma, gallbladder, stomach cancer, hairy cell leukemia, hemangioblastoma, head and neck cancer, hemangiopericytoma, hematologic malignancies, hepatoblastoma, hepatosplenic T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, invasive lobular carcinoma, intestinal cancer, kidney cancer, laryngeal cancer, premelanoma, lethal intermediate carcinoma, leukemia, Leydig cell tumor, liposarcoma, lung cancer, lymphangioma, lymphangiosarcoma,Lymphoepithelioma, lymphoma, acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, liver cancer, small cell lung cancer, non-small cell lung cancer, MALT lymphoma, malignant fibrous histiocytosis, malignant peripheral nerve sheath tumor, malignant triton tumor, mantle cell lymphoma, marginal zone B-cell lymphoma, mast cell leukemia, mediastinal teratoma, germ cell tumor, medullary carcinoma of the breast, medullary thyroid cancer, medulloblastoma, melanoma, meningioma, Merkel cell carcinoma, mesothelioma, metastatic urothelial carcinoma, mixed Mullerian tumor, mucinous tumor, multiple myeloma, muscular neoplasm, myxosporia, myxoid liposarcoma, myxoma, myxosarcoma, nasopharyngeal carcinoma, schwannoma, neuroblastoma, neurofibroma, neuroma, nodular melanoma, ocular cancer, oligodendroglial epithelioma, oligodendroglioma, Eosinophilic granulosa cell tumor, optic nerve sheath meningioma, optic nerve tumor, oral cancer, osteosarcoma, ovarian cancer, Pancoast tumor, papillary thyroid cancer, adrenal crystallomas, pineoblastomas, pinealomas, granular cell tumors, pituitary adenomas, pituitary tumors, plasmacytoma, multigerminomas, precursor T-lymphoblastic lymphoma, primary central nervous system lymphoma, primary effusion lymphoma, primary peritoneal cancer, prostate cancer, pancreatic cancer, pharyngeal cancer, pseudomyxoma of the peritoneum, renal cell carcinoma, renal medullary carcinoma, retinoblastoma, rhabdomyomas, rhabdomyosarcoma, Richter transformation, rectal cancer, sarcomas, schwannomatosis, seminoma, Sertoli cell tumors, sex cord stromal tumors, signet ring cell carcinomas, skin cancer, blue tumors composed of small round cells, small cell carcinomas, soft tissue sarcomas, somatostatin tumors, smoky The cancers may include, but are not limited to, verrucous, spinal tumors, splenic marginal zone lymphoma, squamous cell carcinoma, synovial sarcoma, Sezary disease, small bowel cancer, squamous carcinoma, gastric cancer, T-cell lymphoma, testicular cancer, peritoneal cell carcinoma, thyroid cancer, transitional cell carcinoma, pharyngeal cancer, ureteral carcinoma, genitourinary cancer, urothelial carcinoma, uveal melanoma, uterine cancer, verrucous carcinoma, optic pathway glioma, vulvar cancer, vaginal cancer, Waldenström's macroglobulinemia, Warthin's tumor, and Wilms' tumor. Specifically, the cancers may include, but are not limited to, adenocarcinoma, adult T-cell leukemia / lymphoma, bladder cancer, blastoma, bone cancer,Breast cancer, brain cancer, carcinoma, myeloid sarcoma, cervical cancer, colorectal cancer, esophageal cancer, gastrointestinal cancer, glioblastoma multiforme, glioma, gallbladder, stomach cancer, head and neck cancer, Hodgkin's lymphoma, non-Hodgkin's lymphoma, bowel cancer, kidney cancer, laryngeal cancer, leukemia, lung cancer, lymphoma, liver cancer, small cell lung cancer, non-small cell lung cancer, mesothelioma, multiple myeloma, acute myeloid leukemia (AML), diffuse large B-cell lymphoma (DLBCL), eye cancer, optic nerve tumor, oral cancer, ovarian cancer, pituitary tumor, primary central nervous system lymphoma, prostate cancer, pancreatic cancer, pharyngeal cancer, renal cell carcinoma, rectal cancer, sarcoma, skin cancer, spinal tumor, small intestine cancer, stomach cancer, T-cell lymphoma, testicular cancer, thyroid cancer, throat cancer, genitourinary cancer, urothelial carcinoma, uterine cancer, vaginal cancer, or Wilms' tumor There is. More specifically, the cancer may be ovarian cancer.

[0111] Specifically, the compound of formula I of the present invention, its solvate, stereoisomer or a pharmaceutically acceptable salt thereof can prevent or treat cancer, and the cancer may be, but is not limited to, ovarian cancer.

[0112] In addition, from the experimental results of the examples, the compound of chemical formula I of the present invention has an effect of inhibiting BET protein and can exhibit excellent therapeutic effects on various cancer-related diseases.

[0113] In this specification, the c-Myc gene was discovered as a causative gene for Burkitt's lymphoma cells. Since then, mutations that enhance the stability of the c-Myc protein and increased expression due to gene amplification have been recognized in many types of cancer, and c-Myc is thought to be a gene deeply involved in tumorigenesis. Overexpression of the c-Myc gene occurs in many cancer cells, and the c-Myc gene is an important target for cancer treatment, and treatment is being conducted by suppressing c-Myc expression levels.

[0114] As used herein, the term "treating" or "treatment" means inhibiting a disease, condition or disorder, e.g., inhibiting the disease, condition or disorder in a subject experiencing or exhibiting the pathology or signs of the disease, condition or disorder, i.e., preventing further development of the pathology and / or signs, or ameliorating a disease, condition or disorder, e.g., ameliorating the disease, condition or disorder in a subject experiencing or exhibiting the pathology or signs of the disease, condition or disorder, i.e., reversing the pathology and / or signs, e.g., reducing the severity of the disease.

[0115] As used herein, the term "preventing" or "prevention" refers to preventing a disease, condition or disorder, for example, in a subject who may be predisposed to the disease, condition or disorder but does not yet experience or exhibit the pathology or signs of the disease.

[0116] In one embodiment, the pharmaceutical composition may include conventional pharmaceutically acceptable carriers, excipients, or additives. The pharmaceutical composition may be formulated according to conventional methods and may be prepared in various oral dosage forms such as tablets, pills, powders, capsules, syrups, emulsions, and microemulsions, or in parenteral dosage forms such as intramuscular, intravenous, or subcutaneous administration.

[0117] When the pharmaceutical composition of the present invention is manufactured in the form of an oral dosage form, examples of additives or carriers used include cellulose, calcium silicate, corn starch, lactose, sucrose, dextrose, calcium phosphate, stearic acid, magnesium stearate, calcium stearate, gelatin, talc, surfactants, suspending agents, emulsifiers, diluents, etc. When the pharmaceutical composition of the present invention is manufactured in the form of an injection, examples of additives or carriers include water, saline solution, glucose aqueous solution, pseudo-sugar aqueous solution, alcohol, glycol, ether (e.g., polyethylene glycol 400), oil, fatty acid, fatty acid ester, glyceride, surfactant, suspending agent, emulsifier, etc.

[0118] The dosage of the pharmaceutical composition is an amount effective for the treatment or prevention of an individual or patient, and may be administered orally or parenterally depending on the purpose. In the case of oral administration, the amount is 3 to 20 mg, more specifically 5 to 10 mg, per kg of body weight per day based on the active ingredient. In the case of parenteral administration, the amount is 3 to 20 mg, more specifically 5 to 10 mg, per kg of body weight per day based on the active ingredient. It should be understood that the dosage for a specific individual or patient should be determined in light of various related factors such as the patient's weight, age, sex, health condition, diet, administration time, administration method, and severity of the disease, and may be appropriately increased or decreased by a specialist. The dosage is not intended to limit the scope of the present invention in any way. A doctor or veterinarian having ordinary skill in the relevant art can easily determine and prescribe an effective amount of the required pharmaceutical composition. For example, a physician or veterinarian may start the dosage of a compound of the present invention used in a pharmaceutical composition at a level lower than that required to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.

[0119]

[0120] Hereinafter, the present invention will be described in more detail through examples. These examples are intended solely to illustrate the present invention more specifically, and it will be apparent to those skilled in the art that the scope of the present invention is not limited by these examples, in accordance with the gist of the present invention.

[0121] [Manufacturing example]

[0122] The structure of the compound in the present invention was confirmed by nuclear magnetic resonance (NMR) and mass spectrometry (MS). NMR was measured using a Bruker Avance 300 instrument. The solvent for the measurement was deuterium-substituted dimethyl sulfoxide (DMSO-d6), and the internal standard was tetramethylsilane (TMS).

[0123] Mass spectrometry was measured using a Waters ACQUITY Qda instrument and analyzed in electrospray ionization (ESI) positive ion mode.

[0124] The known starting materials of the present invention can be prepared by conventional synthetic methods in the art, or can be purchased from Sigma-Aldrich, TCI, Wako, Kanto, Fluorchem, Acros, Alfa, Fluka, Combi-Blocks, Dae-Jung, etc.

[0125] Compounds 1 to 104 of the present invention were prepared according to the following manufacturing examples and examples.

[0126] Manufacturing Example 1: Manufacturing of 4-methoxy-7-(1-methyl-6-oxo-3-pyridiyl)benzo[b]thiophene-2-carboxylic acid

[0127] Manufacturing Example 1-1: Manufacturing of methyl 7-bromo-4-methoxybenzo[b]thiophene-2-carboxylate

[0128]

[0129] 2-Fluoro-6-methoxybenzaldehyde (20.0 g, 130 mmol, 1 eq) was first dissolved in dimethylformamide (120 ml), and methyl 2-mercaptoacetate (20.6 g, 194 mmol, 1.5 eq) and potassium carbonate (26.9 g, 194.5 mmol) were added dropwise, and the mixture was stirred at 15°C for 3 hours. Upon completion of the reaction, the reaction product was diluted with 1 N HCl aqueous solution (100.0 ml). The mixture was washed with ethyl acetate (140 ml, 3 times) and water (120 ml, 3 times). The organic layer was dried over anhydrous magnesium sulfate, filtered, and the filtrate was distilled under reduced pressure to obtain an intermediate product (22.9 g, 79.0% yield).

[0130] The intermediate product was dissolved in dimethylformamide (200 ml), bromine (16.4 g, 103.0 mmol) was added, and the mixture was stirred at 15°C for 12 hours. Upon completion of the reaction, the reactant was diluted with 1 N HCl aqueous solution (10.0 ml), extracted with ethyl acetate (40 ml, 3 times), and washed with water (50 ml, 3 times). The organic layer was dried over anhydrous magnesium sulfate, filtered, and the filtrate was distilled under reduced pressure to obtain the product (25.3 g, 81.5% yield).

[0131] 1 H-NMR (300MHz, DMSO-d6)δ8(s, 1H), 7.45(d, 1H), 7.02(d, 1H), 3.87(s, 3H), 3.79(s, 3H)

[0132] Manufacturing Example 1-2: Manufacturing of methyl 4-methoxy-7-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)benzo[b]thiophene-2carboxylate

[0133]

[0134] The compound (10.0 g, 33.2 mmol, 1 eq) obtained in Manufacturing Example 1-1 is dissolved in a mixed solution of dioxane (100 mL) and water (20 mL). 1-Methyl-5-(4,4,5,5,-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one (8.59 g, 36.5 mmol, 1.1 eq), potassium carbonate (13.7 g, 99.6 mmol, 3 eq), and Pd(dppf)Cl2 (2.43 g, 3.32 mmol, 0.1 eq) are added. The reaction mixture is stirred at 100°C for 2 hours under a nitrogen stream. Upon completion of the reaction, cool to room temperature and extract with ethyl acetate (200 mL) and water (300 mL, 3 times). The organic layer was dried over anhydrous magnesium sulfate, and the filtered filtrate was distilled under reduced pressure to obtain the product (9.33 g, 78.4% yield).

[0135] 1 H-NMR (300MHz, DMSO-d6) δ8.76(s, 1H), 8(s, 1H), 7.31(d, 1H), 7.08(d, 1H), 6.95(d, 1H), 6.44(d, 1H), 3.87(s, 3H), 3.79(s, 3H), 3.3(s, 3H)

[0136] Manufacturing Example 1-3: Manufacturing of 4-methoxy-7-(1-methyl-6-oxo-3-pyridiyl)benzo[b]thiophene-2-carboxylic acid

[0137]

[0138] The compound obtained in Manufacturing Example 1-2 was dissolved in a mixture of tetrahydrofuran (84.0 mL) and water (28 mL), and then lithium hydroxide (9.51 g, 226 mmol) was added. The reaction mixture was stirred at 25°C for 12 hours. When the reaction was complete, the solvent was removed under reduced pressure, and the remainder was diluted with water (20.0 mL). 1 N HCl aqueous solution was added until the pH of the mixture became 3.0, and then extracted with ethyl acetate (200 mL, twice). The organic layer was dried over anhydrous magnesium sulfate, filtered, and the filtrate was distilled under reduced pressure to obtain the product (8.00 g, 89.5% yield).

[0139] 1 H-NMR (300MHz, DMSO-d6) δ13.4(s, OH), 8.76(s, 1H), 8.14(s, 1H), 7.31(d, 1H), 7.08(d, 1H), 6.95(d, 1H), 6.44(d, 1H), 3.79(s, 3H), 3.3(s, 3H)

[0140] Manufacturing Example 2: Manufacturing of methyl 3-(benzylamino)propanoate

[0141]

[0142] Tetraethylamine (6.95 g, 68.7 mmol, 1.2 eq) was added dropwise to a solution of phenylmethylamine (6.15 g, 57.2 mmol, 1 eq) and methanol (90 mL). Methyl acrylate (5.42 g, 62.9 mmol, 5.66 mL, 1.1 eq) was slowly added dropwise to the solution and stirred at 25°C for 1 hour. When the reaction was complete, water (100 mL) was added and extracted with ethyl acetate (150 mL, 3 times). The organic layer was dried over anhydrous magnesium sulfate, filtered, and the filtrate was distilled under reduced pressure to obtain the product (9.52 g, 86.3% yield).

[0143] 1 H-NMR (300MHz, DMSO-d6)δ7.29-7.35(m, 5H), 4.16(s, NH), 3.76(s, 2H), 3.6(s, 3H), 2.94(t, 2H), 2.51(t, 2H)

[0144] Example 1: Synthesis of N-benzyl-4-methoxy-7-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-N-(3-(methylamino)-3-oxopropyl)benzo[b]thiophene-2-carboxamide

[0145]

[0146] 4-Methoxy-7-(1-methyl-6-oxo-3-pyridiyl)benzo[b]thiophene-2-carboxylic acid (8.00 g, 25.3 mmol, 1 eq) obtained in Preparation Example 1 and methyl 3-(benzylamino)propanoate (4.38 g, 25.3 mmol, 1 eq) obtained in Preparation Example 2 are dissolved in dimethylformaldehyde (80 ml), and diisopropylethylamine (DIEA, 16.3 g, 126 mmol, 5 eq) and O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU, 14.4 g, 38.1 mmol, 1.5 eq) are added. The mixture is stirred at 25°C for 12 hours. After the reaction was completed, the reaction product was washed with water (300 ml) and extracted with ethyl acetate (500 ml, 3 times). The organic layer was dried over anhydrous magnesium sulfate, filtered, and the filtrate was distilled under reduced pressure to obtain an intermediate product. The intermediate product was dissolved in a MeNH2 / ethanol solution (51.1 g, 740 mmol, 30% purity) and stirred at 40°C for 2 hours. The reaction product was distilled under reduced pressure to remove the solvent, obtaining the product (6.38 g, 51.3% yield, 97.6% purity).

[0147] 1 H-NMR (300MHz, DMSO-d6) δ8.76(s, 1H), 8.45(s, 1H), 7.5 (s, NH), 7.36(m, 2H), 7.29-7.31(m, 4H), 7.08(d, 1H), 6.95(d, 1H), 6.44(d, 1H), 4.67(s, 2H), 3.79(s, 3H), 3.30(t, 3H), 3.24(t, 2H), 2.80(s, 3H), 2.66(d, 2H)

[0148] MS m / z: 490 (M+H) +

[0149]

[0150] In the following Examples 2 to 26, the compounds were synthesized using the same method as Example 1, or by using appropriate reactants in consideration of the structure of the compound to be synthesized.

[0151] Example 2: Synthesis of N-(4-cyanobenzyl)-4-methoxy-7-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-N-(3-(methylamino)-3-oxopropyl)benzo[b]thiophene-2-carboxamide

[0152]

[0153] 1 H-NMR (300MHz, DMSO-d6) δ8.76(s, 1H), 8.45(s, 1H), 7.76(d, 2H), 7.5 (s, NH), 7.46(m, 2H), 7.31(d, 1H), 7.08(d, 1H), 6.95(d, 1H), 6.44(d, 1H), 4.67(s, 1H), 3.79(s, 1H), 3.30(m, 3H), 3.24(m, 2H), 2.80(s, 3H), 2.66(t, 2H)

[0154] MS m / z: 515 (M+H) +

[0155] Example 3: Synthesis of N-(cyclohexylmethyl)-4-methoxy-7-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-N-(3-(methylamino)-3-oxopropyl)benzo[b]thiophene-2-carboxamide

[0156]

[0157] 1 H-NMR (300MHz, DMSO-d6) δ8.76(s, 1H), 8.45(s, 1H), 7.5 (s, NH), 7.31(d, 1H), 7.08(d, 1H), 6.95(d, 1H), 6.44(d, 1H), 3.79(s, 3H), 3.30(s, 3H), 3.24(t, 2H), 2.83(m, 2H), 2.80(m, 3H), 2.66(t, 2H), 2.06(m, 1H), 1.46-1.63(m, 5H)

[0158] MS m / z: 496 (M+H) +

[0159] Example 4: Synthesis of 4-methoxy-7-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-N-(3-(methylamino)-3-oxopropyl)-N-(2-morpholinoethyl)benzo[b]thiophene-2-carboxamide

[0160]

[0161] 1 H-NMR (300MHz, DMSO-d6) δ8.76(s, 1H), 8.45(s, 1H), 7.5 (s, NH), 7.31(d, 1H), 7.08(d, 1H), 6.95(d, 1H), 6.44(d, 1H), 3.79(s, 3H), 3.52(m, 4H), 3.30(s, 3H), 3.24(t, 2H), 3.06(t, 2H), 2.80(s, 3H), 2.66(t, 2H), 2.53(t, 2H), 2.40(m, 4H)

[0162] MS m / z: 513 (M+H) +

[0163] Example 5: Synthesis of N-(2-(4-fluoropiperidin-1-yl)ethyl)-4-methoxy-7-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-N-(3-(methylamino)-3-oxopropyl)benzo[b]thiophene-2-carboxamide

[0164]

[0165] 1 H-NMR (300MHz, DMSO-d6) δ8.76(s, 1H), 8.45(s, 1H), 7.5 (s, NH), 7.31(d, 1H), 7.08(d, 1H), 6.95(d, 1H), 6.44(d, 1H), 3.79(s, 3H), 3.33(m, 1H), 3.30(s, 3H), 3.24(t, 2H), 3.06(t, 2H), 2.80(s, 3H), 2.66(t, 2H), 2.51-2.53(m, 6H), 1.78(m, 4H)

[0166] MS m / z: 529 (M+H) +

[0167] Example 6: Synthesis of N-(2-(4-(dimethylamino)piperidin-1-yl)ethyl)-4-methoxy-7-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-N-(3-(methylamino)-3-oxopropyl)benzo[b]thiophene-2-carboxamide

[0168]

[0169] 1 H-NMR (300MHz, DMSO-d6) δ8.76(s, 1H), 8.45(s, 1H), 7.5 (s, NH), 7.31(d, 1H), 7.08(d, 1H), 6.95(d, 1H), 6.44(d, 1H), 3.79(s, 3H), 3.30(s, 3H), 3.24(t, 2H), 3.06(t, 2H), 2.80(s, 3H), 2.51-2.66(m, 9H), 2.26(s, 6H), 1.69(m, 4H)

[0170] MS m / z: 554 (M+H) +

[0171] Example 7: Synthesis of 4-methoxy-7-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-N-(3-(methylamino)-3-oxopropyl)-N-(2-(4-methylpiperazin-1-yl)ethyl)benzo[b]thiophene-2-carboxamide

[0172]

[0173] 1 H-NMR (300MHz, DMSO-d6) δ8.76(s, 1H), 8.45(s, 1H), 7.50(s, NH), 7.31(d, 1H), 7.08(d, 1H), 6.95(d, 1H), 6.44(d, 1H), 3.79(s, 3H), 3.30(s, 3H), 3.24(t, 2H), 3.06(t, 2H), 2.80(s, 3H), 2.66(t, 2H), 2.53(t, 2H), 2.29(m, 8H), 2.14(s, 3H)

[0174] MS m / z: 526 (M+H) +

[0175] Example 8: Synthesis of 4-methoxy-7-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-N-(3-(methylamino)-3-oxopropyl)-N-(pyridin-2-ylmethyl)benzo[b]thiophene-2-carboxamide

[0176]

[0177] 1 H-NMR (300MHz, DMSO-d6) δ8.76(s, 1H), 8.51(d, 1H), 8.45(s, 1H), 7.74(t, 1H), 7.50(s, NH), 7.31(m, 2H), 7.24(t, 1H), 7.08(d, 1H), 6.95(d, 1H), 6.44(d, 1H), 4.55(s, 2H), 3.79(s, 3H), 3.30(s, 3H), 3.24(t, 2H), 2.80(s, 3H), 2.66(t, 2H)

[0178] MS m / z: 491 (M+H) +

[0179] Example 9: Synthesis of N-((6-fluoropyridin-2-yl)methyl)-4-methoxy-7-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-N-(3-(methylamino)-3-oxopropyl)benzo[b]thiophene-2-carboxamide

[0180]

[0181] 1 H-NMR (300MHz, DMSO-d6) δ8.76(s, 1H), 8.45(s, 1H), 8.13(t, 1H), 7.5 (s, NH), 7.43(d, 1H), 7.31(d, 1H), 7.19(t, 1H), 7.08(d, 1H), 6.95(d, 1H), 6.44(d, 1H), 4.55(s, 2H), 3.79(s, 3H), 3.30(s, 3H), 3.24(t, 2H), 2.80(s, 3H), 2.66(t, 2H)

[0182] MS m / z: 509 (M+H) +

[0183] Example 10: Synthesis of 4-methoxy-7-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-N-(3-(methylamino)-3-oxopropyl)-N-((5-methylfuran-2-yl)methyl)benzo[b]thiophene-2-carboxamide

[0184]

[0185] 1 H-NMR (300MHz, DMSO-d6) δ8.76(s, 1H), 8.45(t, 1H), 7.5 (s, NH), 7.31(d, 1H), 7.08(d, 1H), 6.95(d, 1H), 6.44(d, 1H), 6.17(d, 1H), 6.02(d, 1H), 4.07(s, 2H), 3.79(s, 3H), 3.30(s, 3H), 3.24(t, 2H), 2.80(s, 3H), 2.66(t, 2H), 2.20(s, 3H)

[0186] MS m / z: 494 (M+H) +

[0187] Example 11: Synthesis of 4-methoxy-7-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-N-(3-(methylamino)-3-oxopropyl)-N-(1-(oxazol-5-yl)ethyl)benzo[b]thiophene-2-carboxamide

[0188]

[0189] 1 H-NMR (300MHz, DMSO-d6) δ8.76(s, 1H), 8.45(s, 1H), 7.90(s, 1H), 7.5 (s, NH), 7.31(d, 1H), 7.09(m, 2H), 6.95(d, 1H), 6.44(d, 1H), 4.98(q, 1H), 3.79(s, 3H), 3.30(s, 3H), 3.24(t, 2H), 2.80(s, 3H), 2.44(t, 2H), 1.47(d, 3H)

[0190] MS m / z: 495 (M+H) +

[0191] Example 12: Synthesis of 4-methoxy-N-((1-methyl-1H-pyrazol-5-yl)methyl)-7-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-N-(3-(methylamino)-3-oxopropyl)benzo[b]thiophene-2-carboxamide

[0192]

[0193] 1 H-NMR (300MHz, DMSO-d6) δ8.76(s, 1H), 8.45(s, 1H), 7.5 (s, NH), 7.31(d, 1H), 7.21(d, 1H), 7.08(d, 1H), 6.95(d, 1H), 6.44(d, 1H), 6.00(d, 1H), 4.22(s, 2H), 3.79(s, 3H), 3.63(s, 3H), 3.30(s, 3H), 3.24(t, 2H), 2.80(d, 3H), 2.66(t, 2H)

[0194] MS m / z: 494 (M+H) +

[0195] Example 13: Synthesis of N-benzyl-4-methoxy-7-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-N-(2-(oxiran-2-yl)ethyl)benzo[b]thiophene-2-carboxamide

[0196]

[0197] 1 H-NMR (300MHz, DMSO-d6) δ8.76(s, 1H), 8.45(s, 1H), 7.29-7.36(m, 6H), 7.08(d, 1H), 6.95(d, 1H), 6.44(d, 1H), 4.67(s, 2H), 3.79(s, 3H), 3.3(s, 3H), 2.94(t, 2H), 2.61(m, 2H), 2.44(m, 1H), 1.66(q, 2H)

[0198] MS m / z: 475 (M+H) +

[0199] Example 14: Synthesis of N-(4-cyanobenzyl)-4-methoxy-7-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-N-(2-(oxiran-2-yl)ethyl)benzo[b]thiophene-2-carboxamide

[0200]

[0201] 1 H-NMR (300MHz, DMSO-d6) δ8.76(s, 1H), 8.45(s, 1H), 7.76(d, 2H), 7.46(d, 2H), 7.31(d, 1H), 7.08(d, 1H), 6.95(d, 1H), 6.44(d, 1H), 4.67(s, 2H), 3.79(s, 3H), 3.3(s, 3H), 2.94(t, 2H), 2.61(m, 2H), 2.44(m, 1H), 1.66(q, 2H)

[0202] MS m / z: 500 (M+H) +

[0203] Example 15: Synthesis of N-(cyclohexylmethyl)-4-methoxy-7-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-N-(2-(oxiran-2-yl)ethyl)benzo[b]thiophene-2-carboxamide

[0204]

[0205] 1 H-NMR (300MHz, DMSO-d6) δ8.76(s, 1H), 8.45(s, 1H), 7.31(d, 1H), 7.08(d, 1H), 6.95(d, 1H), 6.44(d, 1H), 3.79(s, 3H), 3.3(s, 3H), 2.94(t, 2H), 2.83(d, 2H), 2.61(m, 2H), 2.44(m, 1H), 2.06(q, 1H), 1.63-1.66(m, 6H), 1.46-1.53(m, 6H)

[0206] MS m / z: 481 (M+H) +

[0207] Example 16: Synthesis of 4-methoxy-7-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-N-(2-morpholinoethyl)-N-(2-(oxiran-2-yl)ethyl)benzo[b]thiophene-2-carboxamide

[0208]

[0209] 1 H-NMR (300MHz, DMSO-d6) δ8.76(s, 1H), 8.45(s, 1H), 7.31(d, 1H), 7.08(d, 1H), 6.95(d, 1H), 6.44(d, 1H), 3.79(s, 3H), 3.52(dt, 4H), 3.3(s, 3H), 3.06(t, 2H), 2.94(t, 2H), 2.53-2.61(m, 4H), 2.40-2.44(m, 5H), 1.66(q, 2H)

[0210] MS m / z: 498 (M+H) +

[0211] Example 17: Synthesis of N-(2-(4-fluoropiperidin-1-yl)ethyl)-4-methoxy-7-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-N-(2-(oxiran-2-yl)ethyl)benzo[b]thiophene-2-carboxamide

[0212]

[0213] 1 H-NMR (300MHz, DMSO-d6) δ8.76(s, 1H), 8.45(s, 1H), 7.31(d, 1H), 7.08(d, 1H), 6.95(d, 1H), 6.44(d, 1H), 3.79(s, 3H), 3.33(m, 1H), 3.3(s, 3H), 3.06(t, 2H), 2.94(m, 2H), 2.51-2.61(m, 8H),2.44(m, 1H), 1.66-1.78(m, 4H), 1.78(m, 2H), 1.66(m, 2H)

[0214] MS m / z: 514 (M+H) +

[0215] Example 18: Synthesis of N-(2-(4-(dimethylamino)piperidin-1-yl)ethyl)-4-methoxy-7-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-N-(2-(oxiran-2-yl)ethyl)benzo[b]thiophene-2-carboxamide

[0216]

[0217] 1 H-NMR (300MHz, DMSO-d6) δ8.76(s, 1H), 8.45(s, 1H), 7.31(d, 1H), 7.08(d, 1H), 6.95(d, 1H), 6.44(d, 1H), 3.79(s, 3H), 3.3(s, 3H), 3.06(t, 2H), 2.94(t, 2H), 2.61-2.63(m, 3H),2.51-2.53(m, 6H), 2.44(m, 1H), 2.26(s, 6H), 1.69(m, 4H), 1.66(m, 2H)

[0218] MS m / z: 539 (M+H) +

[0219] Example 19: Synthesis of 4-methoxy-7-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-N-(2-(4-methylpiperazin-1-yl)ethyl)-N-(2-(oxiran-2-yl)ethyl)benzo[b]thiophene-2-carboxamide

[0220]

[0221] 1 H-NMR (300MHz, DMSO-d6) δ8.76(s, 1H), 8.45(s, 1H), 7.31(d, 1H), 7.08(d, 1H), 6.95(d, 1H), 6.44(d, 1H), 3.79(s, 3H), 3.3(s, 3H), 3.06(t, 2H), 2.94(t, 2H), 2.61(t, 2H), 2.53(t, 2H), 2.44(m, 1H), 2.29(m, 8H), 2.14(s, 3H), 1.66(q, 2H)

[0222] MS m / z: 511 (M+H) +

[0223] Example 20: Synthesis of 4-methoxy-7-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-N-(2-(4-methylpiperazin-1-yl)ethyl)-N-(2-(oxiran-2-yl)ethyl)benzo[b]thiophene-2-carboxamide

[0224]

[0225] 1 H-NMR (300MHz, DMSO-d6) δ8.76(s, 1H), 8.51(d, 1H), 8.45(s, 1H), 7.74(t, 1H), 7.31(m, 2H), 7.24(t, 1H), 7.08(d, 1H), 6.95(d, 1H), 6.44(d, 1H), 4.55(s, 2H), 3.79(s, 3H), 3.3(s, 3H), 2.94(t, 2H), 2.44-2.61(m, 3H), 1.66(q, 2H)

[0226] MS m / z: 476 (M+H) +

[0227] Example 21: Synthesis of N-((6-fluoropyridin-2-yl)methyl)-4-methoxy-7-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-N-(2-(oxiran-2-yl)ethyl)benzo[b]thiophene-2-carboxamide

[0228]

[0229] 1 H-NMR (300MHz, DMSO-d6) δ8.76(s, 1H), 8.45(s, 1H), 8.13(q, 1H), 7.43(d, 1H), 7.31(d, 1H), 7.19(t, 1H), 7.08(d, 1H), 6.95(d, 1H), 6.44(d, 1H), 4.55(s, 2H), 3.79(s, 3H), 3.3(s, 3H), 2.94(t, 2H), 2.61(m, 2H), 2.44(m, 1H), 1.66(q, 2H)

[0230] MS m / z: 494 (M+H) +

[0231] Example 22: Synthesis of 4-methoxy-7-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-N-((5-methylfuran-2-yl)methyl)-N-(2-(oxiran-2-yl)ethyl)benzo[b]thiophene-2-carboxamide

[0232]

[0233] 1 H-NMR (300MHz, DMSO-d6) δ8.76(s, 1H), 8.45(s, 1H), 7.31(d, 1H), 7.08(d, 1H), 6.95(d, 1H), 6.44(d, 1H), 6.17(d, 1H), 6.02(d, 1H), 4.07(s, 2H), 3.79(s, 3H), 3.3(s, 3H), 2.94(t, 2H), 2.61(m, 2H), 2.44(m, 1H), 2.2(s, 3H), 1.66(q, 2H)

[0234] MS m / z: 479 (M+H) +

[0235] Example 23: Synthesis of 4-methoxy-7-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-N-(1-(oxazol-5-yl)ethyl)-N-(2-(oxiran-2-yl)ethyl)benzo[b]thiophene-2-carboxamide

[0236]

[0237] 1 H-NMR (300MHz, DMSO-d6) δ8.76(s, 1H), 8.45(s, 1H), 7.90(s, 1H), 7.31(d, 1H), 7.09(m, 2H), 6.95(d, 1H), 6.44(q, 1H), 4.98(q, 1H), 3.79(s, 3H), 3.30(s, 3H), 2.94(t, 2H), 2.61(m, 2H), 2.44(m, 1H), 1.66(q, 2H), 1.47(d, 3H)

[0238] MS m / z: 480 (M+H) +

[0239] Example 24: Synthesis of 4-methoxy-N-((1-methyl-1H-pyrazol-5-yl)methyl)-7-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-N-(2-(oxiran-2-yl)ethyl)benzo[b]thiophene-2-carboxamide

[0240]

[0241] 1 H-NMR (300MHz, DMSO-d6) δ8.76(s, 1H), 8.45(s, 1H), 7.31(d, 1H), 7.21(d, 1H), 7.08(d, 1H), 6.95(d, 1H), 6.44(d, 1H), 6(d, 1H), 4.22(s, 2H), 3.79(s, 3H), 3.63(s, 3H), 3.3(s, 3H), 2.94(t, 2H), 2.61(m, 2H), 2.44(m, 1H), 1.66(q, 2H)

[0242] MS m / z: 479 (M+H) +

[0243] Example 25: Synthesis of 4-methoxy-7-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-N-(2-(oxiran-2-yl)ethyl)-N-(1-(pyridin-2-yl)piperidin-4-yl)benzo[b]thiophene-2-carboxamide

[0244]

[0245] 1 H-NMR (300MHz, DMSO-d6) δ8.76(s, 1H), 8.45(s, 1H), 8.04(d, 1H), 7.55(t, 1H), 7.31(d, 1H), 7.08(d, 1H), 6.95(d, 1H), 6.73(t, 1H), 6.63(d, 1H), 6.44(d, 1H), 3.79(s, 3H), 3.6(m, 1H), 3.3(s, 3H), 3.14(m, 4H), 2.94(t, 2H), 2.61(m, 2H), 2.44(m, 1H), 1.85(m, 4H), 1.66(m, 2H)

[0246] MS m / z: 545 (M+H)+

[0247] Example 26: Synthesis of N-((1H-indazol-3-yl)methyl)-4-methoxy-7-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-N-(2-(oxiran-2-yl)ethyl)benzo[b]thiophene-2-carboxamide

[0248]

[0249] 1 H-NMR (300MHz, DMSO-d6)δ12.4(br, NH), 8.76(s, 1H), 8.45(s, 1H), 8.32(d, 1H), 7.92(d, 1H), 7.65(t, 1H), 7.45(t, 1H), 7.31(d, 1H), 7.08(d, 1H), 6.95(d, 1H), 6.44(d, 1H), 4.22(s, 2H), 3.79(s, 3H), 3.3(s, 3H), 2.94(t, 2H), 2.61(m, 2H), 2.44(m, 1H), 1.66(t, 2H)

[0250] MS m / z: 515 (M+H) +

[0251] Manufacturing Example 3: Manufacturing of 3-methyl-5-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)benzo[b]thiophene-2-carboxylic acid

[0252] Manufacturing Example 3-1: Manufacturing of methyl 5-bromo-3-methylbenzo[b]thiophene-2-carboxylate

[0253]

[0254] 4-Bromo-2-fluoroacetophenone (20.0 g, 92.1 mmol, 1 eq) and DMAP (11.2 g, 92.1 mmol, 1 eq) were first dissolved in dioxane (300 ml), and methyl 2-mercapto acetate (11.7 g, 110.6 mmol, 1.2 eq) was added dropwise, and the mixture was stirred at 15°C for 8 hours. Upon completion of the reaction, the reaction product was diluted with 1 N HCl aqueous solution (10.0 ml). Extracted with ethyl acetate (50 ml, 3 times) and washed with water (60 ml, 3 times). The organic layer was dried over anhydrous magnesium sulfate, filtered, and the filtrate was distilled under reduced pressure to obtain the product (21.2 g, 80.7% yield).

[0255] 1 H-NMR (300MHz, DMSO-d6) δ7.94(s, 1H), 7.86(d, 1H), 7.45(d, 1H), 3.84(s, 3H), 2.7(s, 3H)

[0256] Manufacturing Example 3-2: Manufacturing of methyl 3-methyl-5-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)benzo[b]thiophene-2-carboxylate

[0257]

[0258] The compound (10.0 g, 35.0 mmol, 1 eq) obtained in Manufacturing Example 3-1 is dissolved in a mixed solution of dioxane (100 mL) and water (20 mL). 1-Methyl-5-(4,4,5,5,-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one (9.06 g, 38.5 mmol, 1.1 eq), potassium carbonate (14.4 g, 105.0 mmol, 3 eq), and Pd(dppf)Cl2 (2.56 g, 3.50 mmol, 0.1 eq) are added. The reaction mixture is stirred at 100°C for 2 hours under a nitrogen stream. Upon completion of the reaction, cool to room temperature and extract with ethyl acetate (200 mL) and water (300 mL, 3 times). The organic layer was dried over anhydrous magnesium sulfate, filtered, and the filtrate was distilled under reduced pressure to obtain the product (8.82 g, 80.4% yield).

[0259] 1 H-NMR (300MHz, DMSO-d6) δ8.76(s, 1H), 7.94(d, 1H), 7.87(s, 1H), 7.31(d, 1H), 6.95(d, 1H), 6.44(d, 1H), 3.84(s, 3H), 3.3(s, 3H), 2.7(s, 3H)

[0260] Manufacturing Example 3-3: Manufacturing of 3-methyl-5-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)benzo[b]thiophene-2-carboxylic acid

[0261]

[0262] The compound obtained in Manufacturing Example 3-2 was dissolved in a mixture of tetrahydrofuran (90.0 ml) and water (30 ml), and then lithium hydroxide (10.30 g, 244 mmol) was added. The reaction mixture was stirred at 25°C for 12 hours. When the reaction was completed, the solvent was removed under reduced pressure, and the remainder was diluted with water (20.0 mL). 1 N HCl aqueous solution was added until the pH of the mixture became 3.0, and then extracted with ethyl acetate (200 mL, twice). The organic layer was dried over anhydrous magnesium sulfate, filtered, and the filtrate was distilled under reduced pressure to obtain the product (7.47 g, 88.7% yield).

[0263] 1 H-NMR (300MHz, DMSO-d6)δ13.4(s, OH), 8.76(s, 1H), 7.94(d, 1H), 7.87(d, 1H), 7.31(d, 1H), 6.95(d, 1H), 6.44(d, 1H), 3.3(s, 3H), 2.7(d, 3H)

[0264] Example 27: Synthesis of N-benzyl-3-methyl-5-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-N-(3-(methylamino)-3-oxopropyl)benzo[b]thiophene-2-carboxamide

[0265]

[0266] 3-Methyl-5-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)benzo[b]thiophene-2-carboxylic acid (10.0 g, 33.4 mmol, 1 eq) obtained in Manufacturing Example 3 and methyl 3-(benzylamino)propanoate (5.79 g, 33.4 mmol, 1 eq) obtained in Manufacturing Example 2 are dissolved in dimethylformaldehyde (10 ml), and diisopropylethylamine (DIEA, 21.4, 167.2 mmol, 5 eq) and O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU, 18.9 g, 50.2 mmol, 1.5 eq) are added. The mixture was stirred at 25°C for 12 hours. After the reaction was completed, the reaction product was washed with water (300 ml) and extracted with ethyl acetate (500 ml, 3 times). The organic layer was dried over anhydrous magnesium sulfate, filtered, and the filtrate was distilled under reduced pressure to obtain an intermediate product. The intermediate product was dissolved in a MeNH2 / ethanol solution (67.4 g, 976 mmol, 30% purity) and stirred at 40°C for 2 hours. The reaction product was distilled under reduced pressure to remove the solvent, obtaining the product (7.74 g, 48.9% yield).

[0267] 1 H-NMR (300MHz, DMSO-d6) δ8.76(s, 1H), 7.94(d, 1H), 7.87(s, 1H), 7.5(s, NH), 7.29-7.36(m, 6H), 6.95(d, 1H), 6.44(d, 1H), 4.67(s, 2H), 3.3(s, 3H), 3.24(t, 2H), 2.8(s, 3H), 2.66(t, 2H), 2.6(s, 3H)

[0268] MS m / z: 474 (M+H) +

[0269]

[0270] In the following Examples 28 to 52, the compounds were synthesized using the same method as Example 27, or by using appropriate reactants in consideration of the structure of the compound to be synthesized.

[0271] Example 28: Synthesis of N-(4-cyanobenzyl)-3-methyl-5-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-N-(3-(methylamino)-3-oxopropyl)benzo[b]thiophene-2-carboxamide

[0272]

[0273] 1 H-NMR (300MHz, DMSO-d6) δ8.76(s, 1H), 7.94(d, 1H), 7.87(s, 1H), 7.76(dd, 2H), 7.46-7.5(m, 3H), 7.31(d, 1H), 6.95(d, 1H), 6.44(d, 1H), 4.67(s, 2H), 3.3(s, 3H), 3.24(t, 2H), 2.8(s, 3H), 2.66(t, 2H), 2.6(s, 3H)

[0274] MS m / z: 499 (M+H) +

[0275] Example 29: Synthesis of N-(cyclohexylmethyl)-3-methyl-5-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-N-(3-(methylamino)-3-oxopropyl)benzo[b]thiophene-2-carboxamide

[0276]

[0277] 1 H-NMR (300MHz, DMSO-d6) δ8.76(s, 1H), 7.94(d, 1H), 7.87(s, 1H), 7.5(s, NH), 7.31(d, 1H), 6.95(d, 1H), 6.44(d, 1H), 3.3(s, 3H), 3.24(t, 2H), 2.83(m, 2H), 2.8(m, 3H), 2.66(t, 2H), 2.6(s, 3H), 2.06(m, 1H), 1.63(m, 4H), 1.46-1.53(m, 6H)

[0278] MS m / z: 480 (M+H) +

[0279] Example 30: Synthesis of 3-methyl-5-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-N-(3-(methylamino)-3-oxopropyl)-N-(2-morpholinoethyl)benzo[b]thiophene-2-carboxamide

[0280]

[0281] 1 H-NMR (300MHz, DMSO-d6) δ8.76(s, 1H), 7.94(d, 1H), 7.87(s, 1H), 7.5(s, NH), 7.31(d, 1H), 6.95(d, 1H), 6.44(d, 1H), 3.52(t, 4H), 3.3(s, 3H), 3.24(t, 2H), 3.06(t, 2H), 2.8(s, 3H), 2.66(t, 2H), 2.6(s, 3H), 2.53(t, 2H), 2.4(t, 4H)

[0282] MS m / z: 497 (M+H) +

[0283] Example 31: Synthesis of N-(2-(4-fluoropiperidin-1-yl)ethyl)-3-methyl-5-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-N-(3-(methylamino)-3-oxopropyl)benzo[b]thiophene-2-carboxamide

[0284]

[0285] 1 H-NMR (300MHz, DMSO-d6) δ8.76(s, 1H), 7.94(d, 1H), 7.87(d, 1H), 7.5 (s, NH), 7.31(d, 1H), 6.95(d, 1H), 6.44(d, 1H), 3.33(m, 1H), 3.30(s, 3H), 3.24(t, 2H), 3.06(t, 2H), 2.80(s, 3H), 2.66(t, 2H), 2.60(s, 3H), 2.53(t, 2H), 2.51(t, 4H), 1.78(m, 4H)

[0286] MS m / z: 513 (M+H) +

[0287] Example 32: Synthesis of N-(2-(4-(dimethylamino)piperidin-1-yl)ethyl)-3-methyl-5-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-N-(3-(methylamino)-3-oxopropyl)benzo[b]thiophene-2-carboxamide

[0288]

[0289] 1 H-NMR (300MHz, DMSO-d6) δ8.76(s, 1H), 7.94(d, 1H), 7.87(s, 1H), 7.5(s, NH), 7.31(d, 1H), 6.95(d, 1H), 6.44(d, 1H), 3.3(s, 3H), 3.24(d, 2H), 3.06(d, 2H), 2.8(s, 3H), 2.66(t, 2H), 2.63(s, 1H), 2.6(t, 3H), 2.51-2.53(m, 6H), 2.26(m, 6H), 1.69(m, 4H)

[0290] MS m / z: 538 (M+H) +

[0291] Example 33: Synthesis of 3-methyl-5-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-N-(3-(methylamino)-3-oxopropyl)-N-(2-(4-methylpiperazin-1-yl)ethyl)benzo[b]thiophene-2-carboxamide

[0292]

[0293] 1 H-NMR (300MHz, DMSO-d6) δ8.76(s, 1H), 7.94(d, 1H), 7.87(s, 1H), 7.5(s, NH), 7.31(d, 1H), 6.95(d, 1H), 6.44(d, 1H), 3.3(s, 3H), 3.24(t, 2H), 3.06(t, 2H), 2.8(s, 3H), 2.66(t, 2H), 2.6(s, 3H), 2.53(t, 2H), 2.29(m, 8H), 2.14(s, 3H)

[0294] MS m / z: 510 (M+H)+

[0295] Example 34: Synthesis of 3-methyl-5-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-N-(3-(methylamino)-3-oxopropyl)-N-(pyridin-2-ylmethyl)benzo[b]thiophene-2-carboxamide

[0296]

[0297] 1 H-NMR (300MHz, DMSO-d6) δ8.76(s, 1H), 8.51(d, 1H), 7.94(d, 1H), 7.87(s, 1H), 7.74(t, 1H), 7.5(s, NH), 7.31(d, 1H), 7.31(d, 1H), 7.24(t, 1H), 6.95(d, 1H), 6.44(d, 1H), 4.55(s, 2H), 3.3(d, 3H), 3.24(t, 2H), 2.8(d, 3H), 2.66(t, 2H), 2.6(d, 3H)

[0298] MS m / z: 475 (M+H) +

[0299] Example 35: Synthesis of N-((6-fluoropyridin-2-yl)methyl)-3-methyl-5-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-N-(3-(methylamino)-3-oxopropyl)benzo[b]thiophene-2-carboxamide

[0300]

[0301] 1 H-NMR (300MHz, DMSO-d6) δ8.76(s, 1H), 8.13(t, 1H), 7.94(d, 1H), 7.87(s, 1H), 7.5(s, NH), 7.43(d, 1H), 7.31(d, 1H), 7.19(t, 1H), 6.95(d, 1H), 6.44(d, 1H), 4.55(s, 2H), 3.3(s, 3H), 3.24(t, 2H), 2.8(s, 3H), 2.66(t, 2H), 2.6(s, 3H)

[0302] MS m / z: 493 (M+H)+

[0303] Example 36: Synthesis of 3-methyl-5-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-N-(3-(methylamino)-3-oxopropyl)-N-((5-methylfuran-2-yl)methyl)benzo[b]thiophene-2-carboxamide

[0304]

[0305] 1 H-NMR (300MHz, DMSO-d6) δ8.76(s, 1H), 7.94(d, 1H), 7.87(s, 1H), 7.5(s, NH), 7.31(d, 1H), 6.95(d, 1H), 6.44(d, 1H), 6.17(d, 1H), 6.02(d, 1H), 4.07(s, 2H), 3.3(s, 3H), 3.24(t, 2H), 2.8(s, 3H), 2.66(t, 2H), 2.6(s, 3H), 2.2(s, 3H)

[0306] MS m / z: 478 (M+H) +

[0307] Example 37: Synthesis of 3-methyl-5-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-N-(3-(methylamino)-3-oxopropyl)-N-(1-(oxazol-5-yl)ethyl)benzo[b]thiophene-2-carboxamide

[0308]

[0309] 1 H-NMR (300MHz, DMSO-d6) δ8.76(s, 1H), 7.87-7.94(m, 3H), 7.5(s, NH), 7.31(d, 1H), 7.09(s, 1H), 6.95(d, 1H), 6.44(d, 1H), 4.98(q, 1H), 3.3(s, 3H), 3.24(t, 2H), 2.8(s, 3H), 2.6(s, 3H), 2.44(t, 2H), 1.47(d, 3H)

[0310] MS m / z: 479 (M+H) +

[0311] Example 38: Synthesis of 3-methyl-N-((1-methyl-1H-pyrazol-5-yl)methyl)-6-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-N-(3-(methylamino)-3-oxopropyl)benzo[b]thiophene-2-carboxamide

[0312]

[0313] 1 H-NMR (300MHz, DMSO-d6) δ8.76(s, 1H), 7.94(d, 1H), 7.87(s, 1H), 7.5(s, NH), 7.31(d, 1H), 7.21(d, 1H), 6.95(d, 1H), 6.44(d, 1H), 6(d, 1H), 4.22(s, 2H), 3.63(s, 3H), 3.3(s, 3H), 3.24(t, 2H), 2.8(s, 3H), 2.66(t, 2H), 2.6(s, 3H)

[0314] MS m / z: 478 (M+H) +

[0315] Example 39: Synthesis of N-benzyl-N-(4-hydroxybutyl)-3-methyl-5-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)benzo[b]thiophene-2-carboxamide

[0316]

[0317] 1 H-NMR (300MHz, DMSO-d6) δ8.76(s, 1H), 7.94(d, 1H), 7.87(s, 1H), 7.29-7.36(m, 6H), 6.95(d, 1H), 6.44(d, 1H), 4.67(s, 2H), 4.14(s, OH), 3.46(t, 2H), 3.3(s, 3H), 2.94(t, 2H), 2.6(s, 3H), 1.52-1.57(m, 4H)

[0318] MS m / z: 461 (M+H) +

[0319] Example 40: Synthesis of N-(4-cyanobenzyl)-N-(4-hydroxybutyl)-3-methyl-5-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)benzo[b]thiophene-2-carboxamide

[0320]

[0321] 1 H-NMR (300MHz, DMSO-d6) δ8.76(s, 1H), 7.94(d, 1H), 7.87(s, 1H), 7.76(dd, 2H), 7.46(dd, 2H), 7.31(d, 1H), 6.95(d, 1H), 6.44(d, 1H), 4.67(s, 2H), 4.14(s, OH), 3.46(t, 2H), 3.3(s, 3H), 2.94(t, 2H), 2.6(s, 3H), 1.52-1.57(m, 4H)

[0322] MS m / z: 486 (M+H) +

[0323] Example 41: Synthesis of N-(cyclohexylmethyl)-N-(4-hydroxybutyl)-3-methyl-5-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)benzo[b]thiophene-2-carboxamide

[0324]

[0325] 1 H-NMR (300MHz, DMSO-d6) δ8.76(s, 1H), 7.94(d, 1H), 7.87(d, 1H), 7.31(d, 1H), 6.95(d, 1H), 6.44(d, 1H), 4.14(s, OH), 3.46(t, 2H), 3.3(s, 3H), 2.94(t, 2H), 2.83(d, 2H), 2.6(s, 3H), 2.06(m, 1H), 1.46-1.63(m, 14H)

[0326] MS m / z: 467 (M+H) +

[0327] Example 42: Synthesis of N-(4-hydroxybutyl)-3-methyl-5-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-N-(2-morpholinoethyl)benzo[b]thiophene-2-carboxamide

[0328]

[0329] 1 H-NMR (300MHz, DMSO-d6) δ8.76(s, 1H), 7.94(d, 1H), 7.87(s, 1H), 7.31(d, 1H), 6.95(d, 1H), 6.44(d, 1H), 4.14(s, OH), 3.52(m, 2H), 3.46(m, 2H), 3.3(s, 3H), 3.06(t, 2H), 2.94(t, 2H), 2.6(s, 3H), 2.53(t, 2H), 2.4(dt, 4H), 1.52-1.57(m, 4H)

[0330] MS m / z: 484 (M+H) +

[0331] Example 43: Synthesis of N-(2-(4-fluoropiperidin-1-yl)ethyl)-N-(4-hydroxybutyl)-3-methyl-5-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)benzo[b]thiophene-2-carboxamide

[0332]

[0333] 1 H-NMR (300MHz, DMSO-d6) δ8.76(s, 1H), 7.94(d, 1H), 7.87(s, 1H), 7.31(d, 1H), 6.95(d, 1H), 6.44(d, 1H), 4.14(s, OH), 3.46(m, 2H), 3.33(m, 1H), 3.3(m, 3H), 3.06(t, 2H), 2.94(t, 2H), 2.6(m, 3H), 2.51-2.53(m, 6H), 1.78(m, 4H), 1.52-1.57(m, 4H)

[0334] MS m / z: 500 (M+H) +

[0335] Example 44: Synthesis of N-(2-(4-(dimethylamino)piperidin-1-yl)ethyl)-N-(4-hydroxybutyl)-3-methyl-5-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)benzo[b]thiophene-2-carboxamide

[0336]

[0337] 1 H-NMR (300MHz, DMSO-d6) δ8.76(s, 1H), 7.94(d, 1H), 7.87(s, 1H), 7.31(d, 1H), 6.95(d, 1H), 6.44(d, 1H), 4.14(s, OH), 3.46(t, 2H), 3.3(s, 3H), 3.06(t, 2H), 2.94(t, 2H), 2.63(m, 1H), 2.6(s, 3H), 2.51-2.53(m, 6H), 2.20-2.26(m, 6H),1.52-1.69(m, 8H)

[0338] MS m / z: 525 (M+H) +

[0339] Example 45: Synthesis of N-(4-hydroxybutyl)-3-methyl-5-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-N-(2-(4-methylpiperazin-1-yl)ethyl)benzo[b]thiophene-2-carboxamide

[0340]

[0341] 1 H-NMR (300MHz, DMSO-d6) δ8.76(s, 1H), 7.94(d, 1H), 7.87(s, 1H), 7.31(d, 1H), 6.95(d, 1H), 6.44(d, 1H), 4.14(s, OH), 3.46(t, 2H), 3.3(s, 3H), 3.06(t, 2H), 2.94(t, 2H), 2.6(s, 3H), 2.53(t, 2H), 2.29(m, 8H), 2.14(s, 3H), 1.52-1.57(m, 4H)

[0342] MS m / z: 497 (M+H) +

[0343] Example 46: Synthesis of N-(4-hydroxybutyl)-3-methyl-5-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-N-(pyridin-2-ylmethyl)benzo[b]thiophene-2-carboxamide

[0344]

[0345] 1 H-NMR (300MHz, DMSO-d6) δ8.76(s, 1H), 8.51(d, 1H), 7.94(d, 1H), 7.87(s, 1H), 7.74(t, 1H), 7.31(dd, 2H), 7.24(t, 1H), 6.95(d, 1H), 6.44(d, 1H), 4.55(s, 2H), 4.14(s, OH), 3.46(t, 2H), 3.3(s, 3H), 2.94(t, 2H), 2.6(s, 3H), 1.52-1.57(m, 4H)

[0346] MS m / z: 462 (M+H) +

[0347] Example 47: Synthesis of N-((6-fluoropyridin-2-yl)methyl)-N-(4-hydroxybutyl)-3-methyl-5-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)benzo[b]thiophene-2-carboxamide

[0348]

[0349] 1 H-NMR (300MHz, DMSO-d6) δ8.76(s, 1H), 8.13(t, 1H), 7.94(d, 1H), 7.87(s, 1H), 7.43(d, 1H), 7.31(d, 1H), 7.19(t, 1H), 6.95(d, 1H), 6.44(d, 1H), 4.55(s, 2H), 4.14(s, OH), 3.46(t, 2H), 3.3(s, 3H), 2.94(t, 2H), 2.6(s, 3H), 1.52-1.57(m, 4H)

[0350] MS m / z: 480 (M+H) +

[0351] Example 48: Synthesis of N-(4-hydroxybutyl)-3-methyl-5-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-N-((5-methylfuran-2-yl)methyl)benzo[b]thiophene-2-carboxamide

[0352]

[0353] 1 H-NMR (300MHz, DMSO-d6) δ8.76(s, 1H), 7.94(d, 1H), 7.87(s, 1H), 7.31(d, 1H), 6.95(d, 1H), 6.44(d, 1H), 6.17(d, 1H), 6.02(d, 1H), 4.14(s, OH), 4.07(s, 2H), 3.46(t, 2H), 3.3(s, 3H), 2.94(t, 2H), 2.6(s, 3H), 2.2(s, 3H), 1.52-1.57(m, 4H)

[0354] MS m / z: 465

[0355] Example 49: Synthesis of N-(4-hydroxybutyl)-3-methyl-5-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-N-(1-(oxazol-5-yl)ethyl)benzo[b]thiophene-2-carboxamide

[0356]

[0357] 1 H-NMR (300MHz, DMSO-d6) δ8.76(s, 1H), 7.87-7.94(m, 3H), 7.31(d, 1H), 7.09(s, 1H), 6.95(d, 1H), 6.44(d, 1H), 4.98(q, 1H), 4.14(s, OH), 3.46(t, 2H), 3.3(s, 3H), 2.94(t, 2H), 2.6(s, 3H), 1.53-1.57(m, 4H), 1.47(d, 3H)

[0358] MS m / z: 466 (M+H) +

[0359] Example 50: Synthesis of N-(4-hydroxybutyl)-3-methyl-N-((1-methyl-1H-pyrazol-5-yl)methyl)-5-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)benzo[b]thiophene-2-carboxamide

[0360]

[0361] 1 H-NMR (300MHz, DMSO-d6) δ8.76(s, 1H), 7.94(d, 1H), 7.87(s, 1H), 7.31(d, 1H), 7.21(d, 1H), 6.95(d, 1H), 6.44(d, 1H), 6(d, 1H), 4.22(s, 2H), 4.14(s, OH), 3.63(s, 3H), 3.46(t, 2H), 3.3(s, 3H), 2.94(t, 2H), 2.6(s, 3H), 1.52-1.57(m, 4H)

[0362] MS m / z: 465 (M+H) +

[0363] Example 51: Synthesis of N-(4-hydroxybutyl)-3-methyl-5-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-N-(1-(pyridin-2-yl)piperidin-4-yl)benzo[b]thiophene-2-carboxamide

[0364]

[0365] 1 H-NMR (300MHz, DMSO-d6) δ8.76(s, 1H), 8.04(d, 1H), 7.94(d, 1H), 7.87(s, 1H), 7.55(t, 1H), 7.31(d, 1H), 6.95(d, 1H), 6.73(t, 1H), 6.63(d, 1H), 6.44(d, 1H), 4.14(s, 1H), 3.6(m, 1H), 3.46(t, 2H), 3.3(s, 3H), 3.14(m, 4H), 2.94(t, 2H), 2.6(s, 3H), 1.85(m, 4H), 1.52-1.57(m, 4H)

[0366] MS m / z: 531 (M+H) +

[0367] Example 52: Synthesis of N-((1H-indazol-3-yl)methyl)-N-(4-hydroxybutyl)-3-methyl-5-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)benzo[b]thiophene-2-carboxamide

[0368]

[0369] 1 H-NMR (300MHz, DMSO-d6) δ12.4(s, NH), 8.76(s, 1H), 8.32(d, 1H), 7.92-7.94(m, 2H), 7.87(t, 1H), 7.65(t, 1H), 7.45(t, 1H), 7.31(d, 1H), 6.95(d, 1H), 6.44(d, 1H), 4.22(s, 2H), 4.14(s, OH), 3.46(t, 2H), 3.3(s, 3H), 2.94(t, 2H), 2.6(s, 3H), 1.52-1.57(m, 4H)

[0370] MS m / z: 501 (M+H) +

[0371] Manufacturing Example 4: Preparation of 5-methoxy-7-(1-methyl-6-oxo-3-pyridiyl)benzo[b]thiophene-2-carboxylic acid

[0372] Manufacturing Example 4-1: Manufacturing of methyl 7-bromo-5-methoxybenzo[b]thiophene-2-carboxylate

[0373]

[0374] 2-Fluoro-5-methoxybenzaldehyde (20.0 g, 130 mmol, 1 eq) was first dissolved in dimethylformamide (120 ml), and methyl 2-mercaptoacetate (20.6 g, 194 mmol, 1.5 eq) and potassium carbonate (26.9 g, 194.5 mmol) were added dropwise, and the mixture was stirred at 15°C for 3 hours. Upon completion of the reaction, the reaction product was diluted with 1 N HCl aqueous solution (100.0 ml). The mixture was washed with ethyl acetate (140 ml, 3 times) and water (120 ml, 3 times). The organic layer was dried over anhydrous magnesium sulfate, filtered, and the filtrate was distilled under reduced pressure to obtain an intermediate product (24.1 g, 83.1% yield).

[0375] The intermediate product was dissolved in dimethylformamide (200 ml), bromine (16.9 g, 106.1 mmol) was added, and the mixture was stirred at 15°C for 12 hours. Upon completion of the reaction, the reactant was diluted with 1 N HCl aqueous solution (10.0 ml), extracted with ethyl acetate (40 ml, 3 times), and washed with water (50 ml, 3 times). The organic layer was dried over anhydrous magnesium sulfate, filtered, and the filtrate was distilled under reduced pressure to obtain the product (22.7 g, 73.1% yield).

[0376] 1 H-NMR (300MHz, DMSO-d6)δ8.22(s, 1H), 8.21(s, 1H), 7.1(s, 1H), 3.87(s, 3H), 3.81(s, 3H)

[0377] Manufacturing Example 4-2: Manufacturing of methyl 5-methoxy-7-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)benzo[b]thiophene-2carboxylate

[0378]

[0379] The compound (10.0 g, 33.2 mmol, 1 eq) obtained in Manufacturing Example 4-1 is dissolved in a mixed solution of dioxane (100 mL) and water (20 mL). 1-Methyl-5-(4,4,5,5,-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one (8.59 g, 36.5 mmol, 1.1 eq), potassium carbonate (13.7 g, 99.6 mmol, 3 eq), and Pd(dppf)Cl2 (2.43 g, 3.32 mmol, 0.1 eq) are added. The reaction mixture is stirred at 100°C for 2 hours under a nitrogen stream. Upon completion of the reaction, cool to room temperature and extract with ethyl acetate (200 mL) and water (300 mL, 3 times). The organic layer was dried over anhydrous magnesium sulfate, filtered, and the filtrate was distilled under reduced pressure to obtain the product (8.51 g, 71.5% yield).

[0380] 1 H-NMR (300MHz, DMSO-d6) δ8.76(s, 1H), 8.22(s, 1H), 8.15(s, 1H), 6.97(d, 2H), 6.44(d, 1H), 3.87(s, 6H), 3.3(d, 3H)

[0381] Manufacturing Example 4-3: Manufacturing of 5-methoxy-7-(1-methyl-6-oxo-3-pyridiyl)benzo[b]thiophene-2-carboxylic acid

[0382]

[0383] The compound obtained in Manufacturing Example 4-2 was dissolved in a mixture of tetrahydrofuran (84.0 mL) and water (28 mL), and then lithium hydroxide (9.51 g, 226 mmol) was added. The reaction mixture was stirred at 25°C for 12 hours. When the reaction was complete, the solvent was removed under reduced pressure, and the remainder was diluted with water (20.0 mL). 1 N HCl aqueous solution was added until the pH of the mixture became 3.0, and then extracted with ethyl acetate (200 mL, twice). The organic layer was dried over anhydrous magnesium sulfate, filtered, and the filtrate was distilled under reduced pressure to obtain the product (7.88 g, 90.4% yield).

[0384] 1 H-NMR (300MHz, DMSO-d6) δ13.4(s, OH), 8.76(s, 1H), 8.36(s, 1H), 8.15(s, 1H), 6.97(d, 1H), 6.95(d, 1H), 6.44(d, 1H), 3.87(s, 3H), 3.3(d, 3H)

[0385] Example 53: Synthesis of N-benzyl-5-methoxy-7-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-N-(3-(methylamino)-3-oxopropyl)benzo[b]thiophene-2-carboxamide

[0386]

[0387] 5-Methoxy-7-(1-methyl-6-oxo-3-pyridiyl)benzo[b]thiophene-2-carboxylic acid (8.00 g, 25.3 mmol, 1 eq) obtained in Preparation Example 4 and methyl 3-(benzylamino)propanoate (4.38 g, 25.3 mmol, 1 eq) obtained in Preparation Example 2 are dissolved in dimethylformaldehyde (80 ml), and diisopropylethylamine (DIEA, 16.3 g, 126 mmol, 5 eq) and O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU, 14.4 g, 38.1 mmol, 1.5 eq) are added. The mixture is stirred at 25°C for 12 hours. After the reaction was completed, the reaction product was washed with water (300 ml) and extracted with ethyl acetate (500 ml, 3 times). The organic layer was dried over anhydrous magnesium sulfate, filtered, and the filtrate was distilled under reduced pressure to obtain an intermediate product. The intermediate product was dissolved in a MeNH2 / ethanol solution (51.1 g, 740 mmol, 30% purity) and stirred at 40°C for 2 hours. The reaction product was distilled under reduced pressure to remove the solvent, obtaining the product (6.08 g, 48.9% yield, 91.3% purity).

[0388] 1H-NMR (300MHz, DMSO-d6) δ8.76(s, 1H), 8.45(s, 1H), 8.15(s, 1H), 7.5(s, NH), 7.29-7.36(m, 5H), 6.97(d, 2H), 6.44(d, 1H), 4.67(s, 2H), 3.87(s, 3H), 3.3(s, 3H), 3.24(t, 2H), 2.8(s, 3H), 2.66(t, 2H)

[0389] MS m / z: 490 (M+H) +

[0390]

[0391] In the following Examples 54 to 78, the compounds were synthesized in the same manner as in Example 53, or by using appropriate reactants in consideration of the structure of the compound to be synthesized.

[0392] Example 54: Synthesis of N-(4-cyanobenzyl)-5-methoxy-7-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-N-(3-(methylamino)-3-oxopropyl)benzo[b]thiophene-2-carboxamide

[0393]

[0394] 1 H-NMR (300MHz, DMSO-d6) δ8.76(s, 1H), 8.45(s, 1H), 8.15(s, 1H), 7.76(d, 2H), 7.5(s, NH), 7.46(d, 2H), 6.97(d, 2H), 6.44(d, 1H), 4.67(s, 2H), 3.87(s, 3H), 3.3(s, 3H), 3.24(t, 2H), 2.8(d, 3H), 2.66(t, 2H)

[0395] MS m / z: 515 (M+H) +

[0396] Example 55: Synthesis of N-(cyclohexylmethyl)-5-methoxy-7-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-N-(3-(methylamino)-3-oxopropyl)benzo[b]thiophene-2-carboxamide

[0397]

[0398] 1 H-NMR (300MHz, DMSO-d6) δ8.76(s, 1H), 8.45(s, 1H), 8.15(s, 1H), 7.5(s, NH), 6.97(d, 2H), 6.44(d, 1H), 3.87(s, 3H), 3.3(s, 3H), 3.24(t, 2H), 2.8-2.83(m, 5H), 2.66(t, 2H), 2.06(m, 1H), 1.63(m, 4H), 1.46-1.53(m, 6H)

[0399] MS m / z: 496 (M+H) +

[0400] Example 56: Synthesis of 5-methoxy-7-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-N-(3-(methylamino)-3-oxopropyl)-N-(2-morpholinoethyl)benzo[b]thiophene-2-carboxamide

[0401]

[0402] 1 H-NMR (300MHz, DMSO-d6) δ8.76(s, 1H), 8.45(s, 1H), 8.15(s, 1H), 7.5(s, 4H), 6.97(d, 2H), 6.44(d, 1H), 3.87(s, 3H), 3.52(dt, 4H), 3.3(s, 3H), 3.24(t, 2H), 3.06(t, 2H), 2.8(s, 3H), 2.66(t, 2H), 2.53(t, 2H), 2.4(dt, 4H)

[0403] MS m / z: 513 (M+H) +

[0404] Example 57: Synthesis of N-(2-(4-fluoropiperidin-1-yl)ethyl)-5-methoxy-7-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-N-(3-(methylamino)-3-oxopropyl)benzo[b]thiophene-2-carboxamide

[0405]

[0406] 1 H-NMR (300MHz, DMSO-d6) δ8.76(s, 1H), 8.45(s, 1H), 8.15(s, 1H), 7.5(s, NH), 6.97(d, 2H), 6.44(d, 1H), 3.87(s, 3H), 3.33(m, 1H), 3.3(s, 3H), 3.24(t, 2H), 3.06(t, 2H), 2.8(s, 3H), 2.66(t, 2H), 2.53(t, 2H), 2.51(m, 4H), 1.78(m, 4H)

[0407] MS m / z: 529 (M+H) +

[0408] Example 58: Synthesis of N-(2-(4-(dimethylamino)piperidin-1-yl)ethyl)-5-methoxy-7-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-N-(3-(methylamino)-3-oxopropyl)benzo[b]thiophene-2-carboxamide

[0409]

[0410] 1 H-NMR (300MHz, DMSO-d6) δ8.76(s, 1H), 8.45(s, 1H), 8.15(s, 1H), 7.5(s, NH), 6.97(d, 2H), 6.44(d, 1H), 3.87(s, 3H), 3.3(s, 3H), 3.24(t, 2H), 3.06(t, 2H), 2.8(s, 3H), 2.66(t, 2H), 2.63(m, 1H), 2.51-2.53(m, 6H), 2.26(s, 6H), 1.69(m, 4H)

[0411] MS m / z: 554 (M+H) +

[0412] Example 59: Synthesis of 5-methoxy-7-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-N-(3-(methylamino)-3-oxopropyl)-N-(2-(4-methylpiperazin-1-yl)ethyl)benzo[b]thiophene-2-carboxamide

[0413]

[0414] 1 H-NMR (300MHz, DMSO-d6) δ8.76(s, 1H), 8.45(s, 1H), 8.15(s, 1H), 7.5(s, NH), 6.97(d, 2H), 6.44(d, 1H), 3.87(s, 3H), 3.3(s, 3H), 3.24(t, 2H), 3.06(t, 2H), 2.8(s, 3H), 2.66(t, 2H), 2.53(t, 2H), 2.29(m, 8H), 2.14(s, 3H)

[0415] MS m / z: 526 (M+H) +

[0416] Example 60: Synthesis of 5-methoxy-7-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-N-(3-(methylamino)-3-oxopropyl)-N-(pyridin-2-ylmethyl)benzo[b]thiophene-2-carboxamide

[0417]

[0418] 1 H-NMR (300MHz, DMSO-d6) δ8.76(s, 1H), 8.51(d, 1H), 8.45(s, 1H), 8.15(s, 1H), 7.74(t, 1H), 7.5(s, NH), 7.31(d, 1H), 7.24(t, 1H), 6.97(d, 2H), 6.44(d, 1H), 4.55(s, 2H), 3.87(s, 3H), 3.3(s, 3H), 3.24(t, 2H), 2.8(s, 3H), 2.66(t, 2H)

[0419] MS m / z: 491 (M+H) +

[0420] Example 61: Synthesis of N-((6-fluoropyridin-2-yl)methyl)-5-methoxy-7-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-N-(3-(methylamino)-3-oxopropyl)benzo[b]thiophene-2-carboxamide

[0421]

[0422] 1 H-NMR (300MHz, DMSO-d6) δ8.76(s, 1H), 8.45(s, 1H), 8.13-8.15(m, 2H), 7.5(s, NH), 7.43(d, 1H), 7.19(t, 1H), 6.97(d, 2H), 6.44(d, 1H), 4.55(s, 2H), 3.87(s, 3H), 3.3(s, 3H), 3.24(t, 2H), 2.8(s, 3H), 2.66(t, 2H)

[0423] MS m / z: 509 (M+H) +

[0424] Example 62: Synthesis of 5-methoxy-7-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-N-(3-(methylamino)-3-oxopropyl)-N-((5-methylfuran-2-yl)methyl)benzo[b]thiophene-2-carboxamide

[0425]

[0426] 1 H-NMR (300MHz, DMSO-d6) δ8.76(s, 1H), 8.45(s, 1H), 8.15(s, 1H), 7.5(s, NH), 6.97(d, 1H), 6.95(d, 1H), 6.44(d, 1H), 6.17(d, 1H), 6.02(d, 1H), 4.07(s, 2H), 3.87(s, 3H), 3.3(s, 3H), 3.24(t, 2H), 2.8(s, 3H), 2.66(t, 2H), 2.2(s, 3H)

[0427] MS m / z: 494 (M+H) +

[0428] Example 63: Synthesis of 5-methoxy-7-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-N-(3-(methylamino)-3-oxopropyl)-N-(1-(oxazol-5-yl)ethyl)benzo[b]thiophene-2-carboxamide

[0429]

[0430] 1H-NMR (300MHz, DMSO-d6) δ8.76(s, 1H), 8.45(s, 1H), 8.15(s, 1H), 7.9(s, 1H), 7.5(s, NH), 7.09(s, 1H), 6.97(d, 2H), 6.44(d, 1H), 4.98(q, 1H), 3.87(s, 3H), 3.3(s, 3H), 3.24(t, 2H), 2.8(s, 3H), 2.44(t, 2H), 1.47(d, 3H)

[0431] MS m / z: 495 (M+H) +

[0432] Example 64: Synthesis of 5-methoxy-N-((1-methyl-1H-pyrazol-5-yl)methyl)-7-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-N-(3-(methylamino)-3-oxopropyl)benzo[b]thiophene-2-carboxamide

[0433]

[0434] 1 H-NMR (300MHz, DMSO-d6) δ8.76(s, 1H), 8.45(s, 1H), 8.15(s, 1H), 7.5(s, NH), 7.21(d, 1H), 6.97(d, 2H), 6.44(d, 1H), 6(d, 1H), 4.22(s, 2H), 3.87(s, 3H), 3.63(s, 3H), 3.3(s, 3H), 3.24(t, 2H), 2.8(s, 3H), 2.66(t, 2H)

[0435] MS m / z: 494 (M+H) +

[0436] Example 65: Synthesis of N-benzyl-5-methoxy-7-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-N-(3-(methylamino)-3-oxopropyl)benzo[b]thiophene-2-carboxamide

[0437]

[0438] 1H-NMR (300MHz, DMSO-d6)δ9(s, 1H), 8.45(s, 1H), 8.39(s, 1H), 8.37(s, 1H), 8.14(s, 1H), 7.72(s, 1H), 7.5(s, NH), 7.29-7.36(m, 5H), 4.67(s, 2H), 3.83(s, 3H), 3.81(s, 3H), 3.24(t, 2H), 2.8(s, 3H), 2.66(t, 2H)

[0439] MS m / z: 490 (M+H) +

[0440] Example 66: Synthesis of N-(4-cyanobenzyl)-5-methoxy-7-(5-methoxypyridin-3-yl)-N-(3-(methylamino)-3-oxopropyl)benzo[b]thiophene-2-carboxamide

[0441]

[0442] 1 H-NMR (300MHz, DMSO-d6)δ9(s, 1H), 8.45(s, 1H), 8.39(d, 1H), 8.37(s, 1H), 8.14(d, 1H), 7.76(d, 2H), 7.72(s, 1H), 7.5(s, NH), 7.46(d, 2H), 4.67(s, 2H), 3.83(s, 3H), 3.81(s, 3H), 3.24(t, 2H), 2.8(s, 3H), 2.66(t, 2H)

[0443] MS m / z: 515 (M+H) +

[0444] Example 67: Synthesis of N-(cyclohexylmethyl)-5-methoxy-7-(5-methoxypyridin-3-yl)-N-(3-(methylamino)-3-oxopropyl)benzo[b]thiophene-2-carboxamide

[0445]

[0446] 1H-NMR (300MHz, DMSO-d6)δ9(s, 1H), 8.45(s, 1H), 8.39(d, 1H), 8.37(d, 1H), 8.14(s, 1H), 7.72(s, 1H), 7.5(s, NH), 3.83(s, 3H), 3.81(s, 3H), 3.24(t, 2H), 2.8-2.83(m, 5H), 2.66(t, 2H), 2.06(m, 1H), 1.63(m, 4H), 1.46-1.53(m, 6H)

[0447] MS m / z: 496 (M+H) +

[0448] Example 68: Synthesis of 5-methoxy-7-(5-methoxypyridin-3-yl)-N-(3-(methylamino)-3-oxopropyl)-N-(2-morpholinoethyl)benzo[b]thiophene-2-carboxamide

[0449]

[0450] 1 H-NMR (300MHz, DMSO-d6)δ9(s, 1H), 8.45(s, 1H), 8.39(d, 1H), 8.37(d, 1H), 8.14(s, 1H), 7.72(s, 1H), 7.5(s, NH), 3.83(s, 3H), 3.81(s, 3H), 3.52(dt, 4H), 3.24(t, 2H), 3.06(t, 2H), 2.8(d, 3H), 2.66(t, 2H), 2.53(t, 2H), 2.4(dt, 4H)

[0451] MS m / z: 516 (M+H) +

[0452] Example 69: Synthesis of N-(2-(4-fluoropiperidin-1-yl)ethyl)-5-methoxy-7-(5-methoxypyridin-3-yl)-N-(3-(methylamino)-3-oxopropyl)benzo[b]thiophene-2-carboxamide

[0453]

[0454] 1H-NMR (300MHz, DMSO-d6)δ9(s, 1H), 8.45(s, 1H), 8.39(d, 1H), 8.37(d, 1H), 8.14(s, 1H), 7.72(s, 1H), 7.5(s, NH), 3.83(s, 3H), 3.81(s, 3H), 3.33(m, 1H), 3.24(t, 2H), 3.06(t, 2H), 2.8(s, 3H), 2.66(t, 2H), 2.51-2.53(m, 6H), 1.78(m, 4H)

[0455] MS m / z: 529 (M+H) +

[0456] Example 70: Synthesis of N-(2-(4-(dimethylamino)piperidin-1-yl)ethyl)-5-methoxy-7-(5-methoxypyridin-3-yl)-N-(3-(methylamino)-3-oxopropyl)benzo[b]thiophene-2-carboxamide

[0457]

[0458] 1 H-NMR (300MHz, DMSO-d6)δ9(s, 1H), 8.45(s, 1H), 8.39(d, 1H), 8.37(d, 1H), 8.14(s, 1H), 7.72(s, 1H), 7.5(s, NH), 3.83(s, 3H), 3.81(s, 3H), 3.24(t, 2H), 3.06(t, 2H), 2.8(s, 3H), 2.66(d, 2H), 2.63(m, 1H), 2.51-2.53(m, 6H), 2.26(s, 6H), 1.69(m, 4H)

[0459] MS m / z: 554 (M+H) +

[0460] Example 71: Synthesis of 5-methoxy-7-(5-methoxypyridin-3-yl)-N-(3-(methylamino)-3-oxopropyl)-N-(2-(4-methylpiperazin-1-yl)ethyl)benzo[b]thiophene-2-carboxamide

[0461]

[0462] 1H-NMR (300MHz, DMSO-d6)δ9(s, 1H), 8.45(s, 1H), 8.39(d, 1H), 8.37(d, 1H), 8.14(s, 1H), 7.72(s, 1H), 7.5(s, NH), 3.83(s, 3H), 3.81(s, 3H), 3.24(t, 2H), 3.06(t, 2H), 2.8(s, 3H), 2.66(t, 2H), 2.53(t, 2H), 2.29(m, 8H), 2.14(s, 3H)

[0463] MS m / z: 526 (M+H) +

[0464] Example 72: Synthesis of 5-methoxy-7-(5-methoxypyridin-3-yl)-N-(3-(methylamino)-3-oxopropyl)-N-(pyridin-2-ylmethyl)benzo[b]thiophene-2-carboxamide

[0465]

[0466] 1 H-NMR (300MHz, DMSO-d6)δ9(s, 1H), 8.51(t, 1H), 8.45(s, 1H), 8.39(d, 1H), 8.37(d, 1H), 8.14(s, 1H), 7.74(m, 2H), 7.5(s, NH), 7.31(m, 1H), 7.24(m, 1H), 4.55(s, 2H), 3.83(s, 3H), 3.81(s, 3H), 3.24(t, 2H), 2.8(s, 3H), 2.66(t, 2H)

[0467] MS m / z: 491 (M+H) +

[0468] Example 73: Synthesis of N-((6-fluoropyridin-2-yl)methyl)-5-methoxy-7-(5-methoxypyridin-3-yl)-N-(3-(methylamino)-3-oxopropyl)benzo[b]thiophene-2-carboxamide

[0469]

[0470] 1H-NMR (300MHz, DMSO-d6)δ9(s, 1H), 8.45(s, 1H), 8.39(d, 1H), 8.37(d, 1H), 8.14(m, 2H), 7.72(s, 1H), 7.5(s, NH), 7.43(d, 1H), 7.19(t, 1H), 4.55(s, 2H), 3.83(s, 3H), 3.81(s, 3H), 3.24(t, 2H), 2.8(s, 3H), 2.66(t, 2H)

[0471] MS m / z: 509 (M+H) +

[0472] Example 74: Synthesis of 5-methoxy-7-(5-methoxypyridin-3-yl)-N-(3-(methylamino)-3-oxopropyl)-N-((5-methylfuran-2-yl)methyl)benzo[b]thiophene-2-carboxamide

[0473]

[0474] 1 H-NMR (300MHz, DMSO-d6)δ9(s, 1H), 8.45(s, 1H), 8.39(d, 1H), 8.37(d, 1H), 8.14(s, 1H), 7.72(s, 1H), 7.5(s, NH), 6.17(d, 1H), 6.02(d, 1H), 4.07(s, 2H), 3.83(s, 3H), 3.81(s, 3H), 3.24(t, 2H), 2.8(s, 3H), 2.66(t, 2H), 2.2(s, 3H)

[0475] MS m / z: 494 (M+H) +

[0476] Example 75: Synthesis of 5-methoxy-7-(5-methoxypyridin-3-yl)-N-(3-(methylamino)-3-oxopropyl)-N-(1-(oxazol-5-yl)ethyl)benzo[b]thiophene-2-carboxamide

[0477]

[0478] 1H-NMR (300MHz, DMSO-d6)δ9(s, 1H), 8.45(s, 1H), 8.39(d, 1H), 8.37(d, 1H), 8.14(s, 1H), 7.9(s, 1H), 7.72(s, 1H), 7.5(s, NH), 7.09(s, 1H), 4.98(m, 1H), 3.83(s, 3H), 3.81(s, 3H), 3.24(t, 2H), 2.8(s, 3H), 2.44(t, 2H), 1.47(d, 3H)

[0479] MS m / z: 495 (M+H) +

[0480] Example 76: Synthesis of 5-methoxy-7-(5-methoxypyridin-3-yl)-N-((1-methyl-1H-pyrazol-5-yl)methyl)-N-(3-(methylamino)-3-oxopropyl)benzo[b]thiophene-2-carboxamide

[0481]

[0482] 1 H-NMR (300MHz, DMSO-d6)δ9(s, 1H), 8.45(s, 1H), 8.39(d, 1H), 8.37(d, 1H), 8.14(s, 1H), 7.72(s, 1H), 7.5(s, NH), 7.21(d, 1H), 6(d, 1H), 4.22(s, 2H), 3.83(s, 3H), 3.81(s, 3H), 3.63(s, 3H), 3.24(t, 2H), 2.8(s, 3H), 2.66(t, 2H)

[0483] MS m / z: 494 (M+H) +

[0484] Example 77: Synthesis of 5-methoxy-7-(5-methoxypyridin-3-yl)-N-(3-(methylamino)-3-oxopropyl)-N-(1-(pyridin-2-yl)piperidin-4-yl)benzo[b]thiophene-2-carboxamide

[0485]

[0486] 1H-NMR (300MHz, DMSO-d6)δ9(s, 1H), 8.45(s, 1H), 8.39(d, 1H), 8.37(d, 1H), 8.14(s, 1H), 8.04(d, 1H), 7.72(s, 1H), 7.5-7.55(m, 2H), 6.73(t, 1H), 6.63(t, 1H), 3.83(s, 3H), 3.81(s, 3H), 3.6(m, 1H), 3.14-3.24(m, 6H), 2.8(s, 3H), 2.66(t, 2H), 1.85(m, 4H)

[0487] MS m / z: 560 (M+H) +

[0488] Example 78: Synthesis of N-((1H-indazol-3-yl)methyl)-5-methoxy-7-(5-methoxypyridin-3-yl)-N-(3-(methylamino)-3-oxopropyl)benzo[b]thiophene-2-carboxamide

[0489]

[0490] 1 H-NMR (300MHz, DMSO-d6) δ12.4(s, 4H), 9(s, 1H), 8.45(s, 1H), 8.39(d, 1H), 8.37(d, 1H), 8.32(d, 1H), 8.14(s, 1H), 7.92(d, 1H), 7.65-7.72(m, 2H), 7.45-7.5(m, 2H), 4.22(s, 2H), 3.83(s, 3H), 3.81(s, 3H), 3.24(t, 2H), 2.8(s, 3H), 2.66(t, 2H)

[0491] MS m / z: 530 (M+H) +

[0492]

[0493] In the following Examples 79 to 92, the compounds were synthesized using the same method as Example 27, or by using appropriate reactants considering the structure of the compound to be synthesized.

[0494] Example 79: Synthesis of N-benzyl-5-(5-methoxypyridin-3-yl)-3-methyl-N-(3-(methylamino)-3-oxopropyl)benzo[b]thiophene-2-carboxamide

[0495]

[0496] 1 H-NMR (300MHz, DMSO-d6)δ9(s, 1H), 8.39(s, 1H), 8.12(s, 2H), 7.99(d, 1H), 7.72(s, 1H), 7.5(s, NH), 7.29-7.36(m, 5H), 4.67(s, 2H), 3.83(s, 3H), 3.24(t, 2H), 2.8(s, 3H), 2.66(t, 2H), 2.6(s, 3H)

[0497] MS m / z: 474 (M+H) +

[0498] Example 80: Synthesis of N-(4-cyanobenzyl)-5-(5-methoxypyridin-3-yl)-3-methyl-N-(3-(methylamino)-3-oxopropyl)benzo[b]thiophene-2-carboxamide

[0499]

[0500] 1 H-NMR (300MHz, DMSO-d6)δ9(s, 1H), 8.39(s, 1H), 8.12(s, 2H), 7.99(d, 1H), 7.76(dd, 2H), 7.72(s, 1H), 7.5(s, NH), 7.46(dd, 2H), 4.67(s, 2H), 3.83(s, 3H), 3.24(t, 2H), 2.8(s, 3H), 2.66(t, 2H), 2.6(s, 3H)

[0501] MS m / z: 499 (M+H) +

[0502] Example 81: Synthesis of N-(cyclohexylmethyl)-5-(5-methoxypyridin-3-yl)-3-methyl-N-(3-(methylamino)-3-oxopropyl)benzo[b]thiophene-2-carboxamide

[0503]

[0504] 1 H-NMR (300MHz, DMSO-d6)δ9(s, 1H), 8.39(s, 1H), 8.12(s, 2H), 7.99(d, 1H), 7.72(s, 1H), 7.5(s, NH), 3.83(s, 3H), 3.24(t, 2H), 2.8-2.83(m, 5H), 2.66(t, 2H), 2.6(s, 3H), 2.06(m, 1H), 1.63(m, 4H), 1.46-1.53(m, 6H)

[0505] MS m / z: 480 (M+H) +

[0506] Example 82: Synthesis of 5-(5-methoxypyridin-3-yl)-3-methyl-N-(3-(methylamino)-3-oxopropyl)-N-(2-morpholinoethyl)benzo[b]thiophene-2-carboxamide

[0507]

[0508] 1 H-NMR (300MHz, DMSO-d6)δ9(s, 1H), 8.39(s, 1H), 8.12(s, 2H), 7.99(d, 1H), 7.72(s, 1H), 7.5(s, NH), 3.83(s, 3H), 3.52(dt, 4H), 3.24(t, 2H), 3.06(t, 2H), 2.8(s, 3H), 2.66(t, 2H), 2.6(s, 3H), 2.53(t, 2H), 2.4(dt, 4H)

[0509] MS m / z: 497 (M+H) +

[0510] Example 83: Synthesis of N-(2-(4-fluoropiperidin-1-yl)ethyl)-5-(5-methoxypyridin-3-yl)-3-methyl-N-(3-(methylamino)-3-oxopropyl)benzo[b]thiophene-2-carboxamide

[0511]

[0512] 1H-NMR (300MHz, DMSO-d6)δ9(s, 1H), 8.39(s, 1H), 8.12(s, 2H), 7.99(d, 1H), 7.72(s, 1H), 7.5(s, NH), 3.83(s, 3H), 3.33(m, 1H), 3.24(t, 2H), 3.06(t, 2H), 2.8(s, 3H), 2.66(t, 2H), 2.6(s, 3H), 2.51-2.53(m, 6H), 1.78(m, 4H)

[0513] MS m / z: 513 (M+H) +

[0514] Example 84: Synthesis of N-(2-(4-(dimethylamino)piperidin-1-yl)ethyl)-5-(5-methoxypyridin-3-yl)-3-methyl-N-(3-(methylamino)-3-oxopropyl)benzo[b]thiophene-2-carboxamide

[0515]

[0516] 1 H-NMR (300MHz, DMSO-d6)δ9(s, 1H), 8.39(s, 1H), 8.12(s, 2H), 7.99(d, 1H), 7.72(s, 1H), 7.5 (s, NH), 3.83(s, 3H), 3.24(t, 2H), 3.06(t, 2H), 2.80(s, 3H), 2.66(t, 2H), 2.63(s, 1H), 2.60(m, 3H), 2.51-2.53(m, 6H), 2.26(s, 6H), 1.69(m, 4H)

[0517] MS m / z: 538 (M+H) +

[0518] Example 85: Synthesis of 5-(5-methoxypyridin-3-yl)-3-methyl-N-(3-(methylamino)-3-oxopropyl)-N-(2-(4-methylpiperazin-1-yl)ethyl)benzo[b]thiophene-2-carboxamide

[0519]

[0520] 1H-NMR (300MHz, DMSO-d6)δ9(s, 1H), 8.39(s, 1H), 8.12(s, 2H), 7.99(d, 1H), 7.72(s, 1H), 7.5 (s, NH), 3.83(s, 3H), 3.24(t, 2H), 3.06(t, 2H), 2.80(s, 3H), 2.66(t, 2H), 2.60(s, 3H), 2.53(t, 2H), 2.29(m, 8H), 2.14(s, 3H)

[0521] MS m / z: 510 (M+H) +

[0522] Example 86: Synthesis of 5-(5-methoxypyridin-3-yl)-3-methyl-N-(3-(methylamino)-3-oxopropyl)-N-(pyridin-2-ylmethyl)benzo[b]thiophene-2-carboxamide

[0523]

[0524] 1 H-NMR (300MHz, DMSO-d6)δ9(s, 1H), 8.51(t, 1H), 8.39(s, 1H), 8.12(s, 2H), 7.99(d, 1H), 7.72-7.74(m, 2H), 7.5 (s, NH), 7.24-7.31(m, 2H), 4.55(s, 2H), 3.83(s, 3H), 3.24(t, 2H), 2.80(s, 3H), 2.66(t, 2H), 2.60(s, 3H)

[0525] MS m / z: 475 (M+H) +

[0526] Example 87: Synthesis of N-((6-fluoropyridin-2-yl)methyl)-5-(5-methoxypyridin-3-yl)-3-methyl-N-(3-(methylamino)-3-oxopropyl)benzo[b]thiophene-2-carboxamide

[0527]

[0528] 1H-NMR (300MHz, DMSO-d6)δ9(s, 1H), 8.39(s, 1H), 8.13(m, 3H), 7.99(d, 1H), 7.72(s, 1H), 7.5 (s, NH), 7.43(d, 1H), 7.19(t, 1H), 4.55(s, 2H), 3.83(s, 3H), 3.24(t, 2H), 2.80(s, 3H), 2.66(t, 2H), 2.60(s, 3H)

[0529] MS m / z: 493 (M+H) +

[0530] Example 88: Synthesis of 5-(5-methoxypyridin-3-yl)-3-methyl-N-(3-(methylamino)-3-oxopropyl)-N-((5-methylfuran-2-yl)methyl)benzo[b]thiophene-2-carboxamide

[0531]

[0532] 1 H-NMR (300MHz, DMSO-d6)δ9(s, 1H), 8.39(s, 1H), 8.12(s, 2H), 7.99(d, 1H), 7.72(d, 1H), 7.5 (s, NH), 6.17(d, 1H), 6.02(d, 1H), 4.07(s, 2H), 3.83(s, 3H), 3.24(t, 2H), 2.80(s, 3H), 2.66(t, 2H), 2.60(s, 3H), 2.20(s, 3H)

[0533] MS m / z: 478 (M+H) +

[0534] Example 89: Synthesis of 5-(5-methoxypyridin-3-yl)-3-methyl-N-(3-(methylamino)-3-oxopropyl)-N-(1-(oxazol-5-yl)ethyl)benzo[b]thiophene-2-carboxamide

[0535]

[0536] 1H-NMR (300MHz, DMSO-d6)δ9(s, 1H), 8.39(s, 1H), 8.12(s, 2H), 7.99(d, 1H), 7.90(s, 1H), 7.72(s, 1H), 7.5 (s, NH), 7.09(s, 1H), 4.98(m, 1H), 3.83(s, 3H), 3.24(t, 2H), 2.80(s, 3H), 2.60(s, 3H), 2.44(t, 2H), 1.47(d, 3H)

[0537] MS m / z: 479 (M+H) +

[0538] Example 90: Synthesis of 5-(5-methoxypyridin-3-yl)-3-methyl-N-((1-methyl-1H-pyrazol-5-yl)methyl)-N-(3-(methylamino)-3-oxopropyl)benzo[b]thiophene-2-carboxamide

[0539]

[0540] 1 H-NMR (300MHz, DMSO-d6)δ9(s, 1H), 8.39(s, 1H), 8.12(s, 2H), 7.99(d, 1H), 7.72(s, 1H), 7.5 (s, NH), 7.21(d, 1H), 6.00(d, 1H), 4.22(s, 2H), 3.83(s, 3H), 3.63(s, 3H), 3.24(t, 2H), 2.80(s, 3H), 2.66(t, 2H), 2.60(s, 3H)

[0541] MS m / z: 478 (M+H) +

[0542] Example 91: Synthesis of 5-(5-methoxypyridin-3-yl)-3-methyl-N-(3-(methylamino)-3-oxopropyl)-N-(1-(pyridin-2-yl)piperidin-4-yl)benzo[b]thiophene-2-carboxamide

[0543]

[0544] 1H-NMR (300MHz, DMSO-d6)δ9(s, 1H), 8.39(s, 1H), 7.99-8.12(m, 4H), 7.72(s, 1H), 7.5-7.55(m, 2H), 6.73(t, 1H), 6.63(d, 1H), 3.83(s, 3H), 3.60(m, 1H), 3.24(t, 2H), 3.14(m, 4H), 2.80(s, 3H), 2.66(t, 2H), 2.60(s, 3H), 1.85(m, 6H)

[0545] MS m / z: 544 (M+H) +

[0546] Example 92: Synthesis of N-((1H-indazol-3-yl)methyl)-5-(5-methoxypyridin-3-yl)-3-methyl-N-(3-(methylamino)-3-oxopropyl)benzo[b]thiophene-2-carboxamide

[0547]

[0548] 1 H-NMR (300MHz, DMSO-d6) δ12.4(s, NH), 9(s, 1H), 8.39(s, 1H), 8.32(s, 1H), 8.12(s, 2H), 7.92-7.99(m, 2H), 7.65-7.72(m, 2H), 7.45-7.5 (m, 2H), 4.22(s, 2H), 3.83(s, 3H), 3.24(t, 2H), 2.80(s, 3H), 2.66(t, 2H), 2.60(s, 3H)

[0549] MS m / z: 514 (M+H) +

[0550]

[0551] In the following Examples 93 to 104, the compounds were synthesized using the same method as Example 1, or by using appropriate reactants in consideration of the structure of the compound to be synthesized.

[0552] Example 93: Synthesis of N-benzyl-4-methoxy-7-(1-methyl-1H-pyrazol-5-yl)-N-(3-(methylamino)-3-oxopropyl)benzo[b]thiophene-2-carboxamide

[0553]

[0554] 1 H-NMR (300MHz, DMSO-d6) δ8.45(s, 1H), 7.92(d, 1H), 7.5 (s, NH), 7.29-7.36(m, 6H), 7.25(d, 1H), 6.50(d, 1H), 4.67(s, 2H), 3.95(s, 3H), 3.79(s, 3H), 3.24(t, 2H), 2.80(s, 3H), 2.66(t, 2H)

[0555] MS m / z: 463 (M+H) +

[0556] Example 94: Synthesis of N-(4-cyanobenzyl)-4-methoxy-7-(1-methyl-1H-pyrazol-5-yl)-N-(3-(methylamino)-3-oxopropyl)benzo[b]thiophene-2-carboxamide

[0557]

[0558] 1 H-NMR (300MHz, DMSO-d6) δ8.45(s, 1H), 7.92(d, 1H), 7.76(dd, 2H), 7.5 (s, NH), 7.46(dd, 2H), 7.32(d, 1H), 7.25(d, 1H), 6.50(d, 1H), 4.67(s, 2H), 3.95(s, 3H), 3.79(s, 3H), 3.24(t, 2H), 2.80(s, 3H), 2.66(t, 2H)

[0559] MS m / z: 488 (M+H) +

[0560] Example 95: Synthesis of N-(cyclohexylmethyl)-4-methoxy-7-(1-methyl-1H-pyrazol-5-yl)-N-(3-(methylamino)-3-oxopropyl)benzo[b]thiophene-2-carboxamide

[0561]

[0562] 1H-NMR (300MHz, DMSO-d6) δ8.45(s, 1H), 7.92(d, 1H), 7.5 (s, NH), 7.32(d, 1H), 7.25(d, 1H), 6.50(d, 1H), 3.95(s, 3H), 3.79(s, 3H), 3.24(t, 2H), 2.80-2.83(m, 5H), 2.66(t, 2H), 2.06(m, 1H), 1.63(m, 4H), 1.46-1.53(m, 6H)

[0563] MS m / z: 469 (M+H) +

[0564] Example 96: Synthesis of 4-methoxy-7-(1-methyl-1H-pyrazol-5-yl)-N-(3-(methylamino)-3-oxopropyl)-N-(2-morpholinoethyl)benzo[b]thiophene-2-carboxamide

[0565]

[0566] 1 H-NMR (300MHz, DMSO-d6) δ8.45(s, 1H), 7.92(d, 1H), 7.5 (s, NH), 7.32(d, 1H), 7.25(d, 1H), 6.50(d, 1H), 3.95(s, 3H), 3.79(s, 3H), 3.52(dt, 4H), 3.24(t, 2H), 3.06(t, 2H), 2.80(s, 3H), 2.66(t, 2H), 2.53(t, 2H), 2.40(dt, 4H)

[0567] MS m / z: 486 (M+H) +

[0568] Example 97: Synthesis of N-(2-(4-fluoropiperidin-1-yl)ethyl)-4-methoxy-7-(1-methyl-1H-pyrazol-5-yl)-N-(3-(methylamino)-3-oxopropyl)benzo[b]thiophene-2-carboxamide

[0569]

[0570] 1H-NMR (300MHz, DMSO-d6) δ8.45(s, 1H), 7.92(d, 1H), 7.5 (s, NH), 7.32(d, 1H), 7.25(d, 1H), 6.50(d, 1H), 3.95(s, 3H), 3.79(s, 3H), 3.33(m, 1H), 3.24(t, 2H), 3.06(t, 2H), 2.80(s, 3H), 2.66(t, 2H), 2.51-2.53(m, 6H), 1.78(m, 4H)

[0571] MS m / z: 502 (M+H) +

[0572] Example 98: Synthesis of N-(2-(4-(dimethylamino)piperidin-1-yl)ethyl)-4-methoxy-7-(1-methyl-1H-pyrazol-5-yl)-N-(3-(methylamino)-3-oxopropyl)benzo[b]thiophene-2-carboxamide

[0573]

[0574] 1 H-NMR (300MHz, DMSO-d6) δ8.45(s, 1H), 7.92(d, 1H), 7.5 (s, NH), 7.32(d, 1H), 7.25(d, 1H), 6.50(d, 1H), 3.95(s, 3H), 3.79(s, 3H), 3.24(t, 2H), 3.06(t, 2H), 2.80(s, 3H), 2.66(t, 2H), 2.63(m, 1H), 2.51-2.53(m, 6H), 2.26(s, 6H), 1.69(m, 4H)

[0575] MS m / z: 527 (M+H) +

[0576] Example 99: Synthesis of 4-methoxy-7-(1-methyl-1H-pyrazol-5-yl)-N-(3-(methylamino)-3-oxopropyl)-N-(2-(4-methylpiperazin-1-yl)ethyl)benzo[b]thiophene-2-carboxamide

[0577]

[0578] 1H-NMR (300MHz, DMSO-d6) δ8.45(s, 1H), 7.92(d, 1H), 7.5 (s, NH), 7.32(d, 1H), 7.25(d, 1H), 6.50(d, 1H), 3.95(s, 3H), 3.79(s, 3H), 3.24(t, 2H), 3.06(t, 2H), 2.80(s, 3H), 2.66(t, 2H), 2.53(t, 2H), 2.29(m, 8H), 2.14(s, 3H)

[0579] MS m / z: 499 (M+H) +

[0580] Example 100: Synthesis of 4-methoxy-7-(1-methyl-1H-pyrazol-5-yl)-N-(3-(methylamino)-3-oxopropyl)-N-(pyridin-2-ylmethyl)benzo[b]thiophene-2-carboxamide

[0581]

[0582] 1 H-NMR (300MHz, DMSO-d6) δ8.51(d, 1H), 8.45(s, 1H), 7.92(d, 1H), 7.74(t, 1H), 7.5 (s, NH), 7.24-7.32(m, 4H), 6.50(d, 1H), 4.55(s, 2H), 3.95(s, 3H), 3.79(s, 3H), 3.24(t, 2H), 2.80(s, 3H), 2.66(t, 2H)

[0583] MS m / z: 464 (M+H) +

[0584] Example 101: Synthesis of N-((6-fluoropyridin-2-yl)methyl)-4-methoxy-7-(1-methyl-1H-pyrazol-5-yl)-N-(3-(methylamino)-3-oxopropyl)benzo[b]thiophene-2-carboxamide

[0585]

[0586] 1H-NMR (300MHz, DMSO-d6) δ8.45(s, 1H), 8.13(t, 1H), 7.92(d, 1H), 7.5 (s, NH), 7.43(d, 1H), 7.32(d, 1H), 7.19-7.25(m, 2H), 6.50(d, 1H), 4.55(s, 2H), 3.95(s, 3H), 3.79(s, 3H), 3.24(t, 2H), 2.80(s, 3H), 2.66(t, 2H)

[0587] MS m / z: 482 (M+H) +

[0588] Example 102: Synthesis of 4-methoxy-7-(1-methyl-1H-pyrazol-5-yl)-N-(3-(methylamino)-3-oxopropyl)-N-((5-methylfuran-2-yl)methyl)benzo[b]thiophene-2-carboxamide

[0589]

[0590] 1 H-NMR (300MHz, DMSO-d6) δ8.45(s, 1H), 7.92(d, 1H), 7.5 (s, NH), 7.32(d, 1H), 7.25(d, 1H), 6.50(d, 1H), 6.17(d, 1H), 6.02(d, 1H), 4.07(s, 2H), 3.95(s, 3H), 3.79(s, 3H), 3.24(t, 2H), 2.80(s, 3H), 2.66(t, 2H), 2.20(s, 3H)

[0591] MS m / z: 467 (M+H) +

[0592] Example 103: Synthesis of 4-methoxy-7-(1-methyl-1H-pyrazol-5-yl)-N-(3-(methylamino)-3-oxopropyl)-N-(1-(oxazol-5-yl)ethyl)benzo[b]thiophene-2-carboxamide

[0593]

[0594] 1H-NMR (300MHz, DMSO-d6) δ8.45(s, 1H), 7.90-7.92(m, 2H), 7.5 (s, NH), 7.32(d, 1H), 7.25(d, 1H), 7.09(s, 1H), 6.50(d, 1H), 4.98(m, 1H), 3.95(s, 3H), 3.79(s, 3H), 3.24(t, 2H), 2.80(s, 3H), 2.44(t, 2H), 1.47(d, 3H)

[0595] MS m / z: 468 (M+H) +

[0596] Example 104: Synthesis of 4-methoxy-7-(1-methyl-1H-pyrazol-5-yl)-N-((1-methyl-1H-pyrazol-5-yl)methyl)-N-(3-(methylamino)-3-oxopropyl)benzo[b]thiophene-2-carboxamide

[0597]

[0598] 1 H-NMR (300MHz, DMSO-d6) δ8.45(s, 1H), 7.92(d, 1H), 7.5 (s, NH), 7.32(d, 1H), 7.21-7.25(m, 1H), 6.50(d, 1H), 6.00(d, 1H), 4.22(s, 2H), 3.95(s, 3H), 3.79(s, 3H), 3.63(s, 3H), 3.24(t, 2H), 2.80(s, 3H), 2.66(t, 2H)

[0599] MS m / z: 467 (M+H) +

[0600]

[0601] [Example Exam]

[0602] Test Example 1: Binding Test for BRD2 Protein

[0603] In order to confirm the binding affinity of the example compound of the present invention to the BRD2 protein (BRD2-BD1) among BET proteins, the following experiment was conducted. The protein was quantified using BioDrop Duo + (Biochrom, USA) with PBS as a buffer, and then biotinylated using EZ-Link NHS-PEG4-Biotin (ThermoFisher, USA). After fractionation using PD Minitrap G-25 (Cytiva, USA), the degree of biotinylation of the protein was confirmed by mounting the SA sensor on an Octet® R2 (Satorius, Germany) device, and then the compound to be measured for binding affinity and the BRD2-BD1 protein were diluted in PBST, and the binding affinity (K) was measured using the SSA sensor used when measuring binding of small molecule compounds. d ) was measured. The binding force (K d : The smaller the equilibrium dissociation constant (EDC), the stronger the binding affinity. The binding affinity is shown in [Table 2]. Comparative Example 1 used JQ1, a compound known as a BET bromodomain inhibitor (Filippakopoulos et al., Nature, 468 (2010), 1067-1073).

[0604] [Table 2]

[0605]

[0606]

[0607]

[0608]

[0609] As shown in the above [Table 1], when compared with Comparative Example 1, which is a BET inhibitor, the compound of the example according to the present invention exhibited excellent BRD protein inhibitory activity due to its high binding affinity to the BRD2-BD1 protein.

[0610] Test Example 2: Confirmation of c-Myc expression level and anticancer efficacy

[0611] 1. Confirmation of c-Myc expression level in ovarian cancer cell lines

[0612] Human ovarian cancer cell line Caov3 (Korea Cell Line Bank) was cultured in DMEM (Welgene, Korea) medium, and SNU840 and SNU251 (Korea Cell Line Bank) were cultured in 6-well plates at a density of 1.0 × 10 using RPMI1640 (Welgene, Korea) medium. 6 / well and incubate in a 37℃ 5% CO2 incubator for 24 hours.

[0613] After incubation, the cells were washed twice with PBS and a cell pellet was prepared using a cell scraper. RNA was purified from the cell pellet using Ribospin™ (GeneAll, Korea), and the isolated RNA was quantified using BioDrop Duo+ (Biochrom, USA). Afterwards, cDNA was synthesized using the premix of PrimeScript™ RT reagent Kit (Perfect Real Time) (Takara, Japan) and the purified RNA. The synthesized cDNA was mixed with the premix of the TB Green® Premix Ex Taq™ II (Tli RNaseH Plus) (Takara, USA) kit, human GAPDH, ROX, water, cDNA, and c-Myc primer (Cosmogenetech, Korea), and then RT-PCR was performed using a StepOnePlus™ Real-Time PCR System (ThermoFisher, USA) under the conditions of '95℃ 30 sec -> (95℃ 5 sec -> 60℃ 34 sec) * 40 cycles -> 95℃ 15 sec'. The primer sequences used are as shown in [Table 3], and the c-Myc expression levels of each cell line are shown in [Table 4].

[0614] [Table 3]

[0615]

[0616] [Table 4]

[0617]

[0618] As shown in the table above, it was confirmed that the expression level of c-Myc, a tumor promoting factor, increased in the order of SNU251 < SNU840 < Caov3 in the three human ovarian cancer cell lines used in the test examples. Based on these results, the anticancer efficacy of the example compound according to the c-Myc expression level was confirmed.

[0619] 2. In vitro anticancer efficacy test according to c-Myc expression level

[0620] Human ovarian cancer cell line Caov3 (Korea Cell Line Bank) was cultured in DMEM (Welgene, Korea) medium, and SNU840 and SNU251 (Korea Cell Line Bank) were cultured in 96-well plates at 5.0 x 10 using RPMI1640 (Welgene, Korea) medium. 3 / well and cultured for 24 hours in a 5% CO2 incubator at 37°C. After that, each compound of Example and Comparative Example 1 was diluted to 6 concentrations from 100 μM to 1 nM, treated with 100 μl each, and cultured for 72 hours. After treating each well with a reagent using a CCK assay kit (Dong-In LS, D Plus CCK cell viability assay kit), the reaction was carried out for about 1 hour in a 5% CO2 incubator at 37°C, and the absorbance at a wavelength of 450 nm was measured using a Microplate reader (SpectraMax i3x, USA). The obtained results were converted to IC using the GraphPad Prism 5 (GraphPad Software, Inc., San Diego, USA) program. 50 The values ​​were verified and shown in [Table 5].

[0621] [Table 5]

[0622]

[0623]

[0624] As shown in the table above, the compounds of the present invention have IC values ​​compared to Comparative Example 1 (JQ1) for human ovarian cancer cell lines with different c-Myc expression levels. 50 The values ​​were confirmed to show excellent anticancer efficacy, with an average of 29.7 times lower in Caov3, 19.6 times lower in SNU840, and 10.6 times lower in SNU251. In three human ovarian cancer cell lines, the higher the expression level of c-Myc, a tumor-promoting factor, the higher the IC of the example compound.50 This was found to be significantly lower, and through this, the correlation between the c-Myc expression level and the anticancer efficacy of the example compound was confirmed.

Claims

1. A compound of the following formula I, a solvate, a stereoisomer or a pharmaceutically acceptable salt thereof: [Chemical Formula I] In the above formula, X is hydrogen, C 1-6 Alkyl, C 1-6 alkylC(=O)N(Ra)(Rb), cycloalkyl, heterocycloalkyl, aryl or heteroaryl, Y is hydrogen, C 1-6 alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl, Z is -OH, -OC 1-6 Alkyl, hydrogen, C 1-6 Containing at least one selected from the group consisting of alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl, C of the above X 1-6 Alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is C 1-6 At least one of the hydrogens of alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is -OH, heterocycloalkyl, C 3-6 Substituted with at least one member selected from the group consisting of cycloalkyl and heteroaryl, C of the above Y 1-6 Alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is C 1-6 At least one of the hydrogens of alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is -OH, heterocycloalkyl, C 3-6 It is substituted with at least one member selected from the group consisting of cycloalkyl and heteroaryl.

2. In claim 1, The above Ra and Rb are each independently H, C 1-6 Containing at least one selected from the group consisting of alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl, wherein the above R is hydrogen, A compound of formula I, a solvate, a stereoisomer or a pharmaceutically acceptable salt thereof.

3. In claim 1, The above X is C 1-6 Alkyl or C 1-6 AlkylC(=O)N(Ra)(Rb), C above 1-6 Alkyl is C 1-6 At least one of the hydrogens of alkyl is substituted with one or more of -OH or heterocycloalkyl, The above Ra and Rb are each independently H or C 1-6 Containing at least one alkyl, The above heterocycloalkyl is aziridinyl, A compound of formula I, a solvate, a stereoisomer or a pharmaceutically acceptable salt thereof.

4. In claim 1, The above Y is aryl or C 1-6 It is alkyl, C above 1-6 Alkyl is C 1-6 At least one of the hydrogens of alkyl is heterocycloalkyl, C 3-6 Substituted with at least one member selected from the group consisting of cycloalkyl and heteroaryl, The above aryl comprises at least one benzyl or benzyl in which at least one of hydrogen is substituted with CN, C above 3-6 Cycloalkyl is cyclohexyl, The above heterocycloalkyl comprises at least one selected from the group consisting of morpholinyl, piperidinyl and piperazinyl, The above heteroaryl is at least one of hydrogen or carbon, oxygen, carbon, nitrogen, fluorine and C 1-6 A heteroaryl substituted with one or more substituents selected from the group consisting of alkyl, A compound of formula I, a solvate, a stereoisomer or a pharmaceutically acceptable salt thereof.

5. In claim 1, Z is hydrogen, C 1-6 Alkyl, C3 -6 Containing at least one selected from the group consisting of cycloalkyl, heterocycloalkyl, aryl and heteroaryl, The above heteroaryl is at least one of hydrogen or carbon, oxygen, carbon, nitrogen, C 1-6 Alkyl, OC 1-6 Benzyl substituted with one or more substituents selected from the group consisting of alkyl and =O, A compound of formula I, a solvate, a stereoisomer or a pharmaceutically acceptable salt thereof.

6. In claim 1, A compound of formula I, a solvate, a stereoisomer or a pharmaceutically acceptable salt thereof, selected from the group consisting of compounds represented by the following chemical formulas: .

7. In claim 1, A compound of formula I, a solvate, a stereoisomer or a pharmaceutically acceptable salt thereof, selected from the group consisting of compounds represented by the following chemical formulas: .

8. A pharmaceutical composition for preventing or treating cancer, comprising a compound, solvate, stereoisomer or pharmaceutically acceptable salt thereof according to any one of claims 1 to 7 as an active ingredient.

Citation Information

Patent Citations

  • Amide compound and preparation method and application thereof

    CN111848572A

  • Microneedle for Cosmetic Comprising Water-soluble Materials

    KR1020210101838A

  • Heterocyclic compounds, their production and use

    WO1998003505A2

  • Lysyl oxidase-like 2 inhibitors and uses thereof

    WO2018048930A1